

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

Association between physical activity and musculoskeletal pain: an analysis of international data from the ASAP survey

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-059525
Article Type:	Original research
Date Submitted by the Author:	22-Nov-2021
Complete List of Authors:	Rhim, Hye Chang; Metrowest Medical Center; Tufts University School of Medicine Tenforde, Adam; Harvard Medical School, Department of Physical Medicine and Rehabilitation; Spaulding Rehabilitation Hospital Mohr, Lisa; Goethe University Frankfurt, Department of Sports Medicine Hollander, Karsten; MSH Medical School Hamburg, Institute of Interdisciplinary Exercise Science and Sports Medicine Vogt, Lutz; Goethe-Universitat Frankfurt am Main, Department of Sports Medicine Groneberg, David; Goethe University Frankfurt, Institut of Occupational Medicine, Social Medicine and Environmental Medicine Wilke, Jan; Goethe University Frankfurt, Department of Sports Medicine
Keywords:	SPORTS MEDICINE, REHABILITATION MEDICINE, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY, PAIN MANAGEMENT

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

Association between physical activity and musculoskeletal pain: an

analysis of international data from the ASAP survey

Hye Chang Rhim*, Adam Tenforde*, Lisa Mohr, Karsten Hollander, Lutz Vogt, David A.

Groneberg, Jan Wilke⁺

* The first two authors equally contributed to this work

Hye Chang Rhim, MetroWest Medical Center, Tufts University School of Medicine, Framingham, MA, USA

Adam Tenforde, Department of Physical Medicine and Rehabilitation, Harvard Medical School/Spaulding Rehabilitation Hospital, Boston, MA, USA

Lisa Mohr, Department of Sports Medicine, Goethe University Frankfurt, Frankfurt, Germany

Karsten Hollander, Institute of Interdisciplinary Exercise Science and Sports Medicine, Medical School Hamburg, Hamburg, Germany

Lutz Vogt, Department of Sports Medicine, Goethe University Frankfurt, Frankfurt, Germany

David A. Groneberg, Division of Preventive and Sports Medicine, Institute of Occupational, Social, and Environmental Medicine, Goethe University, Frankfurt, Germany

Jan Wilke, Department of Sports Medicine, Goethe University Frankfurt, Frankfurt, Germany

[‡] Corresponding author: Jan Wilke, Department of Sports Medicine, Goethe University Frankfurt, Frankfurt, Germany, Email: <u>wilke@sport.uni-frankfurt.de</u>

BMJ Open

ABSTRACT

Objective: To investigate the association of physical activity (PA) with musculoskeletal pain (MSK-pain).

Design: Cross-sectional study

Setting: 14 countries (Argentina, Australia, Austria, Brazil, Chile, France, Germany, Italy, the Netherlands, Singapore, South Africa, Spain, Switzerland, and the United States of America)

Participants: Individuals aged 18 or older living in participating countries. Recruitment was performed online using promotion by health-related organizations, mailing lists, and social media advertising.

Primary and secondary outcome measures: PA volumes were assessed with an adapted version of the Nordic physical activity questionnaire-short questionnaire. Prevalence of MSK-pain was captured by means of a 20-item checklist of body locations. Based on the WHO recommendation on PA, participants were classified as non-compliers (0-150 min/week), compliers (150-300 min/week), double compliers (300-450 min/week), triple compliers (450-600 min/week), quadruple compliers (600-750 min/week), quintuple compliers (750-900 min/week), and top compliers (more than 900 min/week). Multivariate logistic regression was used to obtain adjusted odds ratios of the association between PA and MSK-pain for each body location, correcting for age, sex, employment status, and depression risk.

Results: Compared to non-compliers, individuals with simple compliance had smaller odds of MSK-pain in one location (thoracic pain, OR 0.77). Double compliance was associated with reduced pain occurrence in six locations (elbow, OR 0.70; forearm, OR 0.63; wrist, OR 0.74; hand, OR 0.57; fingers, OR 0.72; abdomen, OR 0.61). Triple to top compliance was also linked with lower odds of MSK-pain (five locations in triple compliance, three in quadruple compliance, two in quintuple compliance, three in top compliance), but, at the same time, presented increased odds of MSK-pain in some of the other locations.

Conclusion: A dose of 300-450 min WHO-equivalent PA/week may be optimal to reduce MSKpain. Excessive doses of PA may have harmful effects for certain body locations.

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

Strengths and Limitations of this study

- This is the first large-scale analysis of associations between MSK pain and PA considering multiple anatomical locations
- Large sample size enabled to investigate the associations between different degrees of compliance to physical activity recommended by WHO and MSK-pain
- Administration of the survey in 14 countries allowed participation of diverse populations

to beet eview only

- Self-reported data may be subject to recall bias
- Cross-sectional observational design prohibits causal inference

BMJ Open

INTRODUCTION

Musculoskeletal pain (MSK-pain) is a common condition that can have negative physical, psychological, and social impacts.¹ A summary of previous epidemiological studies conducted with diverse techniques and populations revealed that the prevalence of MSK-pain was approximately 30%.² One study reported 15% of 20–72-year-olds were pain-free whereas 15% had MSK-pain every day during the previous year and 58% reported MSK-pain within the past week.³ Musculoskeletal impairments may contribute to functional limitations particularly in developed countries. ² A separate investigation reported that musculoskeletal conditions accounted for 40% of all chronic conditions and contributed to over half of causes for long-term disability.⁴ It has been reported that disability-adjusted life-years (DALYs), which reflects the years of life lost due to premature mortality and years of life lived with disability, increased by 62% between 1990 and 2016 around the world with 20% surge during the ten-year interval from 2006 to 2016.⁵ Given the aging of global population, the burden of MSK disorders is expected to further increase in the future.⁶

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

Achieving sufficient physical activity (PA) is associated with a variety of positive health outcomes such as substantial risk reduction in all-cause mortality⁷ as well as multiple chronic diseases including type 2 diabetes and metabolic syndrome,⁸ cancer,⁸ and cardiovascular disease.⁹ In the light of these positive impacts, World Health Organization (WHO) recommends 150-300 min of moderate-intensity PA, or 75-150 min of vigorous-intensity PA, or aerobic PA with some combination of moderate and vigorous intensities.¹⁰ PA is also considered one of the most important strategies to prevent and manage MSK pain.¹¹ However, most studies focused on the association of PA with non-communicable disease, and there is a literature gap regarding MSK-pain. Furthermore, it is still less clear whether these amounts are sufficient to elicit benefits

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

in terms of addressing MSK-pain. The few available studies examining the relation of regular PA and MSK-pain tended to focus on influence of PA for specific location or diagnoses such as low back pain, neck pain, or osteoarthritis and found inconsistent results.¹² Other studies have evaluated the associations between PA and pain in occupational settings such as among physical therapists or teaching staff.^{13 14} Particularly, the interplay between the volume of PA and MSK-pain within the general population has been less explored.

The purpose of this study was to investigate the association of total PA with MSK-pain by anatomical location (upper vs lower extremity). We hypothesize that greater time spent in PA would reduce overall MSK-pain, but excess time performing PA might contribute to higher pain resulting from associated overuse injuries

METHODS

Study Design

This article presents an analysis of pre-pandemic baseline data on PA and MSK-pain assessed during the ASAP (Activity and Health during the SARS-CoV-2 Pandemic) survey. It was performed between April 3 and May 9, 2020, including participants from 14 countries (Argentina, Australia, Austria, Brazil, Chile, France, Germany, Italy, the Netherlands, Singapore, South Africa, Spain, Switzerland, and the United States of America (USA)).¹⁵⁻¹⁸ Ethical approval was obtained from the ethics committees of the study center and collaborating institutions. All participants provided digital informed consent.

Participants

BMJ Open

Eligibility for participation in the ASAP survey was limited to individuals aged 18 or older living in participating countries. Recruitment was performed online using promotion by health-related organizations, mailing lists, and social media advertising (e.g. Facebook, Instagram, Twitter).

Questionnaire

To capture PA, the ASAP survey incorporated an adapted version of the Nordic Physical Activity Questionnaire-short (NPAQ-short). In detail, with its four questions, the instrument retrospectively assessed the amounts of moderate and combined moderate and vigorous activities (min/week) during leisure and occupational time. The NPAQ-short has been shown to be reliable (test-retest reliability: rho = 0.80 to 0.82) and valid for observing compliance with the WHO recommendations on PA.¹⁹

Prevalence of MSK-pain was captured by means of binary responses (yes/no) to an adapted 20-item checklist from a consensus statement on epidemiological injury reporting.²⁰ Body locations were categorized as follows: neck/cervical spine, shoulder, upper arm, elbow, forearm, wrist, hand, fingers, thoracic spine, ribs, lower back, abdomen, pelvis/gluteal, hip, groin, thigh, knee, lower leg, ankle/Achilles tendon, foot/toe.

Data Processing and Statistical Analysis

Self-reported PA was categorized as multiples of compliance with WHO guidelines which recommend 150-300 minutes/week of moderate activity, 75-150 minutes/week of vigorous activity, or any adequate combination of both.¹⁰ We used the formula (moderate-tovigorous PA – vigorous PA) + vigorous PA *2 to classify participants as non-compliers (0-150

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

min/week), compliers (150-300 min/week), double compliers (300-450 min/week), triple compliers (450-600 min/week), quadruple compliers (600-750 min/week), quintuple compliers (750-900 min/week), and top compliers (more than 900 min/week).

For each body region, univariate logistic regression was conducted to calculate the unadjusted odds ratio (OR) of the association between pain (dependent variable) and PA. In a similar way, univariate logistic regression was then used to identify associations of pain (dependent variable) and potential confounding variables (sex, age, employment status, depression risk). Finally, multivariate logistic regression was performed including these confounding variables (if relevant) to obtain the adjusted ORs and 95% confidence interval (CI) of the association between the volume of PA and pain. All data analyses were conducted using SPSS 22 (SPSS INC., Armonk, NY, USA), and the significance level was set to $\alpha = 0.05$.

Patient and Public Involvement

Members of the target population without medical background were involved in the designing phase of the ASAP questionnaire. They completed the preliminary version of the survey and helped refine and clarify wording of the survey, an involvement which was intended to increase face validity.

RESULTS

Valid datasets were identified for 13,741 participants (38 ± 15 years, 59% females). 2604 individuals did not meet the WHO recommendation of PA while n=2735 belonged to 150-300 min group, n=1957 to 300-450 min group, n=1749 to 450-600 min group, n=1066 to 600-750

BMJ Open

min group, n=849 to 750-900 min group, and n=2781 to 900+ min group. Comprehensive results are summarized in the Table 1 and 2.

Compared to inactive individuals, simple compliance was associated with reduced MSKpain in one body location (thoracic pain, OR 0.77, Table 1). Double compliance increased the number of locations with less pain to six (elbow, OR 0.70; forearm, OR 0.63; wrist, OR 0.74; hand, OR 0.57; fingers, OR 0.72; abdomen, OR 0.61). Although higher amounts of PA were linked to lower pain levels to a variable degree (five body locations in triple compliance, three in quadruple compliance, two in quintuple compliance, three in top compliance), they also showed increased pain in other locations. Specifically, triple compliance was associated with higher pain in thigh (OR 1.41), knee (OR 1.25), and ankle/Achilles tendon (OR 1.47). Quadruple compliance increased pain locations to four, quintuple compliance to six, and top compliance to seven.

Triple compliance was associated with lower odds to have a total of 5 or more (OR 0.75) or 10 or more (OR 0.36) pain locations, and quadruple compliance was associated with lower odds to have 5 or more pain locations (OR 0.73). However, quintuple and top compliances were associated with higher odds of having a minimum one pain location (OR 1.28 and 1.30, respectively).

DISCUSSION

The purpose of the present study was to understand the relation between PA and MSKpain. Previous research focused on the impact of PA on specific locations of MSK-pain (e.g., low back and neck²¹) or certain occupational settings.^{13 14} Our large-scale multinational study is novel in that it identified the associations between different degrees of compliance to PA recommended by WHO and multiple body locations in the general population.

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

Simple guideline compliance (150-300 min per week) was weakly associated with MSK pain, showing lower odds of developing pain only in thoracic spine but higher odds in foot/toes. In contrast, double compliance (300-450 min per week) substantially increased the number of beneficial associations to six and thus seems to represent the optimal dose when PA is undertaken to prevent MSK. Finally, higher levels of PA (triple to top compliance) were associated with less odds of developing pain in multiple upper body locations but paradoxically contributed to higher odds of lower extremity pain. Notably, participating in 300-600 min of PA per week was associated with lower odds of developing pain in upper extremities, neck, and thoracic and lumbar spine. In contrast, participating in greater than 450 min of PA per week was associated with higher odds of developing pain in the lower extremity.

Time spent in PA and pain in neck, back, and upper extremity

A previous systematic review showed that there was limited evidence for no association between PA and neck pain.²¹ However, our study found that participating in PA between 450-900+ min was associated with lower odds of developing pain in neck/cervical spine. Several epidemiological studies have demonstrated that certain postures sustained for prolonged duration combined with sedentary lifestyle were associated with neck pain.²²⁻²⁴ Therefore, increased PA levels may be helpful to consider in those at risk for neck pain.

Association between PA and thoracic spine has been less explored,²⁵ but a recent observational study found that PA less than 150 min per week was associated with reduced thoracic mobility.²⁶ Our findings build on previous research in that PA less than 150 min per week is also associated with higher odds of developing pain in the thoracic spine.

BMJ Open

While it is generally accepted that PA and exercise are beneficial in the management of acute and chronic low back pain, a previous systematic review could not identify either positive or negative relationship.²⁷ One study suggested that the relationship between the level of activity and back pain might be explained by a U-shaped curve that suggests both low and excessive PA may increase the risk of low back pain.²⁸ Our findings partly support this concept as PA of 450-750 min was associated with lower odds of low back pain while lower or higher PA than that range did not have significant association.

Beneficial effects of PA in the range of 300-600 min were also noted in several locations in the upper extremity such as elbow, forearm, wrist, hand, and fingers. PA exceeding 750 min was associated with higher odds of shoulder pain. The underlying mechanisms of how PA modulates pain are not completely understood, but several pathways have been proposed. Animal study findings suggest regular PA may act on the central nervous system (CNS) and alter rate of pain hypersensitivity, dysregulation of pain modulation, and development of chronic pain.²⁹⁻³¹ In humans, it has been proposed that PA may intervene excitability and inhibition in the CNS,³²⁻³⁴ and anti-inflammatory and antioxidant effects of regular PA might diminish the processes contributing to central sensitization.³⁵⁻³⁷ Other proposed mechanisms in humans include the activation of opioid and serotonin pathways³⁸ or involvement of endocannabinoid system³⁹ induced from regular PA which could exert analgesic effects. While further research is needed to elucidate how much and what type of PA can induce such changes to modulate pain, our results suggest that PA between 300-600 mins per week may be sufficient for spinal conditions and upper extremity pain, with PA exceeding 750 min associated with higher likelihood of shoulder pain.

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

Association of PA and lower extremity pain

The association of PA to lower extremity pain was different than what was observed for upper extremity and spine conditions. Our results suggest PA exceeding 450 min was associated with higher odds of MSK-pain in lower extremity. These findings may be partially explained by higher amounts of PA are likely to involve greater use of the lower extremity. In the United States, it has been reported that walking is the most popular form of exercise followed by biking, yard work, strength training, dancing, and running, which are activities that commonly place physical demands through the lower extremity.⁴⁰ Running is one of the most popular exercises in the world and has been shown to result in lower extremity pain in multiple anatomical locations with nearly all (94.7% of runners) reporting experience of pain at least once after running.⁴¹

We also observed that greater PA was associated with a higher number of sites of MSKpain in the lower extremity. A dose response was observed: 450-600 min was associated with pain in three anatomical regions, 600-750 min with pain in four anatomical regions, 750-900 min with five anatomical regions, and 900+ min with six anatomical regions. The optimal PA level to reduce pain in those with existing musculoskeletal lower extremity pain is unknown. A prior study reported that a minimum of 45 total moderate-vigorous min per week was sufficient to elicit improved or sustained high function with lower-extremity symptoms regardless of age, gender, body mass index, or presence of knee osteoarthritis.⁴² Our findings of PA ranging from 150-450 min not increasing the odds of having pain in the lower extremities suggest this range might be appropriate to be safe and promote other health benefits.

Clinical implication

BMJ Open

While the WHO 2020 guidelines on PA recommend 150-300 min of moderate-intensity PA, or 75-150 min of vigorous-intensity PA, or some equivalent combination of moderateintensity and vigorous-intensity aerobic PA per week for optimal health outcomes,¹⁰ the current study suggests that more PA beyond the WHO recommendation may be necessary to decrease the odds of developing pain particularly in the upper extremity. Our findings suggest a target of 300-450 min of PA per week could be optimal for preventing pain in the upper extremity without clear associated higher rate of lower extremity pain. Recognizing concerns on higher prevalence of pain in low back, neck, and thoracic spine increased during the COVID-19 pandemic,¹⁷ PA target of the higher target of 450 min of PA may not be advisable for those with increased concern for lower extremity pain.

Limitation

While our findings are derived from a large-scale multinational study of participants, we do note potential limitations. Self-report of PA and MSK-pain are limited by reporting bias and inaccuracy including risk for over-reporting level of PA.^{43 44} The cross-sectional study design limits our understanding between PA and the etiology of MSK-pain. We are limited in ability in discriminating the types of PA to report of MSK-pain by anatomical locations. Further prospective cohort or interventional studies may further elucidate the best form and dose of PA to address MSK-pain by anatomical location and specific musculoskeletal injury, and additionally investigate the role of MSK-pain intensity instead of using a binary (yes/no) classification.

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

CONCLUSION

Our findings suggest that PA time above the WHO recommendations may prevent pain in multiple locations such as neck, thoracic spine, low back, and in the upper extremities. Especially, undertaking PA for 300-450 min per week may be most beneficial. However, selective individuals who are prone to injuries or suffer from existing degenerative changes in lower extremities may need to be more cautious when exercising above 450 min per week.

to occur terien only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Acknowledgment: The authors acknowledge the valuable help from the following authors with promoting ASAP survey for data collection (in alphabetical order): Benedict Tan, Bernhard Novak, Celso Ramiréz, Chiara Fossati, Christoph Heidt, Daniel E. Lieberman, David Jimenez-Pavon, Evert Verhagen, Fabio Pigozzi, Falk Richter, Fernando Laíño, Johannes Jaunig, Julian David Pillay, Luiz Carlos Hespanhol Junior, Marcela González-Gross, Matteo Sattler, Mireille van Poppel, Pascal Edouard, Steffen Willwacher

Funding: This research received no external funding.

Data Availability Statement: Data are available upon reasonable request

Ethics Statements

-Ethics approval: This study was approved by the ethics committee of the lead university (Goethe University Frankfurt) and also locally from the partners in the participating countries.

-Digital informed consent was obtained from all subjects involved in the study.

Authors Contribution: HCR/AT: data collection, interpretation, drafting and critical revision of the manuscript, LM, KH, LV, DG: data collection, critical revision of the manuscript, JW: conception/design, data collection, interpretation, critical revision of the manuscript

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

REFERENCES

1. Paanar	nen M, T	Faimela S	S, Auviner	n J, et al.	Impact of	of self-r	eported	musculo	oskeletal	pain on
he	ealth-rel	lated qua	lity of life	among y	young ad	ults. Pa	in Med	2011;12	2(1):9-17	

- 2. Cimmino MA, Ferrone C, Cutolo M. Epidemiology of chronic musculoskeletal pain. *Best Pract Res Clin Rheumatol* 2011;25(2):173-83.
- 3. Natvig B, Nessiøy I, Bruusgaard D, et al. Musculoskeletal complaints in a population. Occurrence and localization. *Tidsskr Nor Laegeforen* 1994;114(3):323-27.
- 4. Badley EM, Wang PP. Arthritis and the aging population: projections of arthritis prevalence in Canada 1991 to 2031. *J Rheumatol* 1998;25(1):138-44.
- Collaborators GDaH. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;390(10100):1260-344. doi: 10.1016/s0140-6736(17)32130-x [published Online First: 2017/09/19]
- Smith E, Hoy DG, Cross M, et al. The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study. *Ann Rheum Dis* 2014;73(8):1462-9. doi: 10.1136/annrheumdis-2013-204680 [published Online First: 2014/03/05]
- 7. Ekelund U, Tarp J, Steene-Johannessen J, et al. Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. *BMJ* 2019;366
- 8. Lee I-M, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major noncommunicable diseases worldwide: an analysis of burden of disease and life expectancy. *Lancet* 2012;380(9838):219-29.
- 9. Kyu HH, Bachman VF, Alexander LT, et al. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. BMJ 2016;354
- 10. Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. *Br J Sports Med* 2020;54(24):1451-62.
- Lin I, Wiles L, Waller R, et al. Patient-centred care: the cornerstone for high-value musculoskeletal pain management. *Br J Sports Med* 2020;54(21):1240-42. doi: 10.1136/bjsports-2019-101918 [published Online First: 2020/06/27]
- 12. Geneen LJ, Moore RA, Clarke C, et al. Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. *Cochrane Database Syst Rev* 2017(4)
- Ezzatvar Y, Calatayud J, Andersen L, et al. Are moderate and vigorous leisure-time physical activity associated with musculoskeletal pain? a cross-sectional study among 981 physical therapists. *Am J Health Promot* 2020;34(1):67-70.
- 14. Tami AM, Bika Lele EC, Mekoulou Ndongo J, et al. Epidemiology of Musculoskeletal Disorders among the Teaching Staff of the University of Douala, Cameroon: Association with Physical Activity Practice. *Int J Environ Res Public Health* 2021;18(11):6004.
- 15. Wilke J, Mohr L, Tenforde AS, et al. Activity and health during the SARS-CoV2 pandemic (ASAP): study protocol for a multi-national network trial. *Front Med* 2020;7:302.

BMJ Open

16. Wilke J, Mohr L, Tenforde AS, et al. Restrictercise! Preferences regarding digital home training programs during confinements associated with the COVID-19 pandemic. Int J Environ Res Public Health 2020;17(18):6515.
17. Wilke J, Mohr L, Tenforde AS, et al. A pandemic within the pandemic? Physical activity levels substantially decreased in countries affected by COVID-19. <i>Int J Environ Res</i>
 Public Health 2021;18(5):2235. 18. Wilke J, Hollander K, Mohr L, et al. Drastic reductions in mental well-being observed globally during the COVID-19 pandemic: results from the ASAP survey. <i>Front Med</i> 2021;8:246.
19. Danquah IH, Petersen CB, Skov SS, et al. Validation of the NPAQ-short–a brief questionnaire to monitor physical activity and compliance with the WHO
 recommendations. <i>BMC Public Health</i> 2018;18(1):1-10. 20. Bahr R, Clarsen B, Derman W, et al. International Olympic Committee consensus statement: methods for recording and reporting of epidemiological data on injury and illness in sports 2020 (including the STROBE extension for sports injury and illness surveillance (STROBE-SIIS)). <i>Orthop J Sports Med</i> 2020;8(2):2325967120902908.
21. Sitthipornvorakul E, Janwantanakul P, Purepong N, et al. The association between physical activity and neck and low back pain: a systematic review. <i>Eur Spine J</i> 2011;20(5):677-89.
22. Ortiz-Hernández L, Tamez-González S, Martínez-Alcántara S, et al. Computer use increases the risk of musculoskeletal disorders among newspaper office workers. <i>Arch Med Res</i> 2003;34(4):331-42.
23. Janwantanakul P, Pensri P, Jiamjarasrangsi W, et al. Associations between prevalence of self-reported musculoskeletal symptoms of the spine and biopsychosocial factors among office workers. <i>J Occup Health</i> 2009:0901270054-54.
 Cagnie B, Danneels L, Van Tiggelen D, et al. Individual and work related risk factors for neck pain among office workers: a cross sectional study. <i>Eur Spine J</i> 2007;16(5):679-86. Briggs AM, Smith AJ, Straker LM, et al. Thoracic spine pain in the general population:
prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. <i>BMC Musculoskelet Disord</i> 2009;10(1):1-12.
26. Heneghan NR, Baker G, Thomas K, et al. What is the effect of prolonged sitting and physical activity on thoracic spine mobility? An observational study of young adults in a UK university setting. <i>BMJ Open</i> 2018;8(5):e019371.
27. Hendrick P, Milosavljevic S, Hale L, et al. The relationship between physical activity and low back pain outcomes: a systematic review of observational studies. <i>Eur Spine J</i> 2011;20(3):464-74.
28. Heneweer H, Vanhees L, Picavet HSJ. Physical activity and low back pain: a U-shaped relation? <i>Pain</i> 2009;143(1-2):21-25.
 29. Bobinski F, Ferreira TAA, Córdova MM, et al. Role of brainstem serotonin in analgesia produced by low-intensity exercise on neuropathic pain following sciatic nerve injury in mice. <i>Pain</i> 2015;156(12):2595.
 30. Sluka KA, O'Donnell JM, Danielson J, et al. Regular physical activity prevents development of chronic pain and activation of central neurons. <i>J Appl Physiol</i> 2013;114(6):725-33. 31. Stagg NJ, Mata HP, Ibrahim MM, et al. Regular exercise reverses sensory hypersensitivity in
a rat neuropathic pain model: role of endogenous opioids. <i>Anesthesiology</i> 2011;114(4):940-48.
16

32. Geva N, Defrin R. Enhanced pain modulation among triathletes: a possible explanation for their exceptional capabilities. *Pain* 2013;154(11):2317-23.

- 33. Naugle KM, Ohlman T, Naugle KE, et al. Physical activity behavior predicts endogenous pain modulation in older adults. *Pain* 2017;158(3):383-90.
- 34. Naugle KM, Riley JL. Self-reported physical activity predicts pain inhibitory and facilitatory function. *Med Sci Sports Exerc* 2014;46(3):622.
- 35. Radak Z, Chung HY, Koltai E, et al. Exercise, oxidative stress and hormesis. *Ageing Res Rev* 2008;7(1):34-42.
- 36. Woods JA, Wilund KR, Martin SA, et al. Exercise, inflammation and aging. *Aging Dis* 2012;3(1):130.
- 37. Dhondt E, Danneels L, Van Oosterwijck S, et al. The influence of physical activity on the nociceptive flexion reflex in healthy people. *Eur J Pain* 2021;25(4):774-89.
- 38. Tour J, Löfgren M, Mannerkorpi K, et al. Gene-to-gene interactions regulate endogenous pain modulation in fibromyalgia patients and healthy controls-antagonistic effects between opioid and serotonin-related genes. *Pain* 2017;158(7):1194-203. doi: 10.1097/j.pain.0000000000896 [published Online First: 2017/03/11]
- 39. Tantimonaco M, Ceci R, Sabatini S, et al. Physical activity and the endocannabinoid system: an overview. *Cell Mol Life Sci* 2014;71(14):2681-98.
- 40. Ham SA, Kruger J, Tudor-Locke C. Participation by US adults in sports, exercise, and recreational physical activities. *J Phys Act Health* 2009;6(1):6-14.
- 41. Rhim HC, Kim SJ, Jeon JS, et al. Prevalence and risk factors of running-related injuries in Korean non-elite runners: a cross-sectional survey study. *J Sports Med Phys Fitness* 2021;61(3):413-19. doi: 10.23736/s0022-4707.20.11223-4 [published Online First: 2020/08/04]
- Dunlop DD, Song J, Lee J, et al. Physical activity minimum threshold predicting improved function in adults with Lower-Extremity symptoms. *Arthritis Care Res* 2017;69(4):475-83.
- 43. Valanou E, Bamia C, Trichopoulou A. Methodology of physical-activity and energyexpenditure assessment: a review. *J Public Health* 2006;14(2):58-65.
- 44. Schmier J, Halpern M. Patient recall and recall bias of health state and health status. Expert Rev Pharmacoecon Outcomes Res. 2004; 4 (2): 159–63.

BMJ Open

Table 1. Association of PA with MSK-Pain by Anatomical Locations

00 min Adjusted OR (95% CI) 0.99 (0.87-1.12) 0.92 (0.79-1.06) 0.98 (0.76-1.27) 0.77 (0.57-1.03) 1.08 (0.76-1.52) 1.07 (0.86-1.34) 0.81 (0.62-1.05) 0.91 (0.70-1.19) 0.77 (0.64-0.93) 0.98 (0.68-1.42) 0.93 (0.82-1.06)	300-4 Crude OR (95% CI) 0.76 (0.67-0.88) 0.87 (0.74-1.02) 0.60 (0.44-0.81) 0.64 (0.46-0.89) 0.53 (0.34-0.82) 0.57 (0.43-0.74) 0.44 (0.32-0.61) 0.63 (0.46-0.86) 0.83 (0.69-1.02) 0.74 (0.49-1.11) 0.85	50 min Adjusted OR (95% CI) 0.89 (0.77-1.03) 0.94 (0.79-1.10) 0.81 (0.60-1.11) 0.70 (0.50-0.98) 0.63 (0.40-0.99) 0.74 (0.57-0.98) 0.57 (0.40-0.79) 0.72 (0.52-0.99) 0.90 (0.74-1.10) 0.88 (0.58-1.34)	1	e of WHO Gu i00 min Adjusted OR (95% CI) 0.78 (0.67-0.91) 0.93 (0.79-1.11) 0.76 (0.54-1.05) 0.99 (0.72-1.37) 0.85 (0.55-1.30) 0.81 (0.62-1.07) 0.59 (0.41-0.83) 0.71 (0.51-0.99) 0.78 (0.63-0.97) 0.74 (0.46-1.17)	600-7 Crude OR (95% CI) 0.62 (0.52-0.74) 0.80 (0.66-0.98) 0.62 (0.42-0.89) 0.92 (0.64-1.32) 0.80 (0.50-1.29) 0.79 (0.58-1.06) 0.60 (0.41-0.87) 0.80 (0.56-1.14) 0.69 (0.54-0.89) 1.04	Construction 250 min Adjusted OR (95% CI) 0.75 (0.62-0.90) 0.88 (0.72-1.08) 0.81 (0.55-1.19) 0.93 (0.64-1.37) 0.96 (0.59-1.55) 1.00 (0.74-1.37) 0.74 (0.50-1.09) 0.93 (0.65-1.34) 0.74 (0.57-0.97) 1.18	Crude OR (95% CI) 0.63 0.52-0.77) 1.10 (0.90-1.34 0.89 (0.63-1.28 0.90 (0.60-1.34 (0.43-1.26) 0.74 (0.43-1.26) 0.71 (0.43-1.26) 0.71 (0.43-1.26) 0.71 (0.40-0.91 0.71 (0.48-1.07) 0.54 (0.40-0.73)	(95% CI) 0.82 (0.67-1.00) 1.27 (1.04-1.56) 1.23 (0.85-1.80) 0.94 (0.62-1.42) 0.90 (0.52-1.54) 0.95 (0.67-1.34) 0.77 (0.50-1.18) 0.81 (0.53-1.22) 0.64 (0.47-0.87)	Crude OR (95% CI) 0.59 (0.52-0.67) 0.98 (0.85-1.13) 0.73 (0.56-0.94) 1.19 (0.93-1.53) 0.98 (0.70-1.36) 0.86 (0.70-1.07) 0.57 (0.44-0.75) 0.75 (0.58-0.98) 0.63 (0.52-0.76)	+ min Adjusted OI (95% CI) 0.78 (0.68-0.89) 1.16 (1.00-1.34) 1.01 (0.77-1.33) 1.30 (0.99-1.70) 1.17 (0.82-1.65) 1.15 (0.91-1.44) 0.74 (0.56-0.99) 0.84 (0.64-1.11) 0.77 (0.63-0.93)
(95% CI) 0.99 (0.87-1.12) 0.92 (0.79-1.06) 0.98 (0.76-1.27) 0.77 (0.57-1.03) 1.08 (0.76-1.52) 1.07 (0.86-1.34) 0.81 (0.62-1.05) 0.91 (0.70-1.19) 0.77 (0.64-0.93) 0.98 (0.68-1.42) 0.93 (0.82-1.06)	$\begin{array}{c} (95\%\ {\rm CI})\\ \hline 0.76\\ (0.67-0.88)\\ \hline 0.87\\ (0.74-1.02)\\ \hline 0.60\\ (0.44-0.81)\\ \hline 0.64\\ (0.46-0.89)\\ \hline 0.53\\ (0.34-0.82)\\ \hline 0.57\\ (0.43-0.74)\\ \hline 0.63\\ (0.46-0.86)\\ \hline 0.83\\ (0.69-1.02)\\ \hline 0.74\\ (0.49-1.11)\\ \end{array}$	(95% CI) 0.89 (0.77-1.03) 0.94 (0.79-1.10) 0.81 (0.60-1.11) 0.70 (0.50-0.98) 0.63 (0.40-0.99) 0.74 (0.57-0.98) 0.57 (0.40-0.79) 0.72 (0.52-0.99) 0.90 (0.74-1.10) 0.88 (0.58-1.34)	(95% CI) 0.66 (0.57-0.76) 0.83 (0.71-0.99) 0.56 (0.41-0.77) 0.95 (0.70-1.30) 0.72 (0.47-1.07) 0.63 (0.48-0.82) 0.47 (0.34-0.66) 0.65 (0.47-0.86) 0.71 (0.58-0.88) 0.60	(95% CI) 0.78 (0.67-0.91) 0.93 (0.79-1.11) 0.76 (0.54-1.05) 0.99 (0.72-1.37) 0.85 (0.55-1.30) 0.81 (0.62-1.07) 0.59 (0.41-0.83) 0.71 (0.51-0.99) 0.78 (0.63-0.97) 0.74	(95% CI) 0.62 (0.52-0.74) 0.80 (0.66-0.98) 0.62 (0.42-0.89) 0.92 (0.64-1.32) 0.80 (0.50-1.29) 0.79 (0.58-1.06) 0.60 (0.41-0.87) 0.80 (0.56-1.14) 0.69 (0.54-0.89) 1.04	(95% CI) 0.75 (0.62-0.90) 0.88 (0.72-1.08) 0.81 (0.55-1.19) 0.93 (0.64-1.37) 0.96 (0.59-1.55) 1.00 (0.74-1.37) 0.74 (0.50-1.09) 0.93 (0.65-1.34) 0.74 (0.57-0.97)	(95% CI) 0.63 0.63 0.90-1.34 0.89 (0.63-1.28 0.90 (0.60-1.34) 0.74 0.74 (0.43-1.26) 0.71 (0.43-1.26) 0.71 (0.43-1.26) 0.71 (0.40-0.91) 0.60 0.71 0.71 0.60 0.60 0.60 0.60 0.60 0.60 0.60 0.71 0.71 0.71 0.71 0.71 0.71 0.71 0.71 0.71 0.71 0.71 0.71 0.71 0.71 0.71 0.71 0.71 0.71 0.54 0.54 0.54 0.74 0.54 0.54 0.54 0.54 0.55	(95% CI) 0.82 (0.67-1.00) 1.27 (1.04-1.56) 1.23 (0.85-1.80) 0.94 (0.62-1.42) 0.90 (0.52-1.54) 0.95 (0.67-1.34) 0.77 (0.50-1.18) 0.81 (0.53-1.22) 0.64 (0.47-0.87)	(95% CI) 0.59 (0.52-0.67) 0.98 (0.85-1.13) 0.73 (0.56-0.94) 1.19 (0.93-1.53) 0.98 (0.70-1.36) 0.86 (0.70-1.07) 0.57 (0.44-0.75) 0.75 (0.58-0.98) 0.63 (0.52-0.76)	(95% CI) 0.78 (0.68-0.89) 1.16 (1.00-1.34) 1.01 (0.77-1.33) 1.30 (0.99-1.70) 1.17 (0.82-1.65) 1.15 (0.91-1.44) 0.74 (0.56-0.99) 0.84 (0.64-1.11) 0.77 (0.63-0.93)
$\begin{array}{c} (0.87-1.12)\\ 0.92\\ (0.79-1.06)\\ 0.98\\ (0.76-1.27)\\ 0.77\\ (0.57-1.03)\\ 1.08\\ (0.76-1.52)\\ 1.07\\ (0.86-1.34)\\ 0.81\\ (0.62-1.05)\\ 0.91\\ (0.70-1.19)\\ 0.77\\ (0.64-0.93)\\ 0.98\\ (0.68-1.42)\\ 0.93\\ (0.82-1.06)\\ \end{array}$	$\begin{array}{c} (0.67-0.88)\\ 0.87\\ (0.74-1.02)\\ 0.60\\ (0.44-0.81)\\ 0.64\\ (0.46-0.89)\\ 0.53\\ (0.34-0.82)\\ 0.57\\ (0.43-0.74)\\ 0.44\\ (0.32-0.61)\\ 0.63\\ (0.46-0.86)\\ 0.83\\ (0.69-1.02)\\ 0.74\\ (0.49-1.11)\\ \end{array}$	0.89 (0.77-1.03) 0.94 (0.79-1.10) 0.81 (0.60-1.11) 0.70 (0.50-0.98) 0.63 (0.40-0.99) 0.74 (0.57-0.98) 0.57 (0.40-0.79) 0.72 (0.52-0.99) 0.90 (0.74-1.10) 0.88 (0.58-1.34)	$\begin{array}{c} (0.57 - 0.76) \\ 0.83 \\ (0.71 - 0.99) \\ 0.56 \\ (0.41 - 0.77) \\ 0.95 \\ (0.70 - 1.30) \\ 0.72 \\ (0.47 - 1.07) \\ 0.63 \\ (0.48 - 0.82) \\ 0.47 \\ (0.34 - 0.66) \\ 0.65 \\ (0.47 - 0.86) \\ 0.71 \\ (0.58 - 0.88) \\ 0.60 \end{array}$	(0.67-0.91) 0.93 (0.79-1.11) 0.76 (0.54-1.05) 0.99 (0.72-1.37) 0.85 (0.55-1.30) 0.81 (0.62-1.07) 0.59 (0.41-0.83) 0.71 (0.51-0.99) 0.78 (0.63-0.97) 0.74	$\begin{array}{c} (0.52-0.74)\\ 0.80\\ (0.66-0.98)\\ 0.62\\ (0.42-0.89)\\ 0.92\\ (0.64-1.32)\\ 0.80\\ (0.50-1.29)\\ 0.79\\ (0.58-1.06)\\ 0.60\\ (0.41-0.87)\\ 0.80\\ (0.56-1.14)\\ 0.69\\ (0.54-0.89)\\ 1.04\\ \end{array}$	(0.62-0.90) 0.88 (0.72-1.08) 0.81 (0.55-1.19) 0.93 (0.64-1.37) 0.96 (0.59-1.55) 1.00 (0.74-1.37) 0.74 (0.50-1.09) 0.93 (0.65-1.34) 0.74 (0.57-0.97)	(0.52-0.77) 1.10 (0.90-1.34pg 0.89 (0.63-1.28pg 0.90 (0.60-1.34pg 0.74 (0.43-1.26) 0.71 (0.43-1.26) 0.71 (0.40-0.99pg 0.60 0.60 0.60 0.71 (0.48-1.07pg 0.54 (0.40-0.73pg	(0.67-1.00) 1.27 (1.04-1.56) 1.23 (0.85-1.80) 0.94 (0.62-1.42) 0.90 (0.52-1.54) 0.95 (0.67-1.34) 0.77 (0.50-1.18) 0.81 (0.53-1.22) 0.64 (0.47-0.87)	$\begin{array}{c} (0.52 - 0.67) \\ 0.98 \\ (0.85 - 1.13) \\ 0.73 \\ (0.56 - 0.94) \\ 1.19 \\ (0.93 - 1.53) \\ 0.98 \\ (0.70 - 1.36) \\ 0.86 \\ (0.70 - 1.07) \\ 0.57 \\ (0.44 - 0.75) \\ 0.75 \\ (0.58 - 0.98) \\ 0.63 \\ (0.52 - 0.76) \end{array}$	(0.68-0.89) 1.16 (1.00-1.34) 1.01 (0.77-1.33) 1.30 (0.99-1.70) 1.17 (0.82-1.65) 1.15 (0.91-1.44) 0.74 (0.56-0.99) 0.84 (0.64-1.11) 0.77 (0.63-0.93)
$\begin{array}{c} (0.79 - 1.06) \\ 0.98 \\ (0.76 - 1.27) \\ 0.77 \\ (0.57 - 1.03) \\ 1.08 \\ (0.76 - 1.52) \\ 1.07 \\ (0.86 - 1.34) \\ 0.81 \\ (0.62 - 1.05) \\ 0.91 \\ (0.70 - 1.19) \\ 0.77 \\ (0.64 - 0.93) \\ 0.98 \\ (0.68 - 1.42) \\ 0.93 \\ (0.82 - 1.06) \end{array}$	$\begin{array}{c} (0.74\text{-}1.02)\\ 0.60\\ (0.44\text{-}0.81)\\ 0.64\\ (0.46\text{-}0.89)\\ 0.53\\ (0.34\text{-}0.82)\\ 0.57\\ (0.43\text{-}0.74)\\ 0.44\\ (0.32\text{-}0.61)\\ 0.63\\ (0.46\text{-}0.86)\\ 0.83\\ (0.69\text{-}1.02)\\ 0.74\\ (0.49\text{-}1.11) \end{array}$	(0.79-1.10) 0.81 (0.60-1.11) 0.70 (0.50-0.98) 0.63 (0.40-0.99) 0.74 (0.57-0.98) 0.57 (0.40-0.79) 0.72 (0.52-0.99) 0.90 (0.74-1.10) 0.88 (0.58-1.34)	$\begin{array}{c} (0.71\text{-}0.99)\\ 0.56\\ (0.41\text{-}0.77)\\ 0.95\\ (0.70\text{-}1.30)\\ 0.72\\ (0.47\text{-}1.07)\\ 0.63\\ (0.48\text{-}0.82)\\ 0.47\\ (0.34\text{-}0.66)\\ 0.65\\ (0.47\text{-}0.86)\\ 0.71\\ (0.58\text{-}0.88)\\ 0.60\\ \end{array}$	(0.79-1.11) 0.76 (0.54-1.05) 0.99 (0.72-1.37) 0.85 (0.55-1.30) 0.81 (0.62-1.07) 0.59 (0.41-0.83) 0.71 (0.51-0.99) 0.78 (0.63-0.97) 0.74	(0.66-0.98) 0.62 (0.42-0.89) 0.92 (0.64-1.32) 0.80 (0.50-1.29) 0.79 (0.58-1.06) 0.60 (0.41-0.87) 0.80 (0.56-1.14) 0.69 (0.54-0.89) 1.04	(0.72-1.08) 0.81 (0.55-1.19) 0.93 (0.64-1.37) 0.96 (0.59-1.55) 1.00 (0.74-1.37) 0.74 (0.50-1.09) 0.93 (0.65-1.34) 0.74 (0.57-0.97)	1.10 ((0.90-1.34pp) 0.89 ((0.63-1.28pp) 0.90 ((0.60-1.34) 0.74 ((0.43-1.26) ((0.43-1.26) ((0.50-0.99p) 0.60 ((0.40-0.91pp) 0.71 ((0.48-1.07p) 0.54 ((0.40-0.73p))	1.27 (1.04-1.56) 1.23 (0.85-1.80) 0.94 (0.62-1.42) 0.90 (0.52-1.54) 0.95 (0.67-1.34) 0.77 (0.50-1.18) 0.81 (0.53-1.22) 0.64 (0.47-0.87)	$\begin{array}{c} (0.85\text{-}1.13)\\ 0.73\\ (0.56\text{-}0.94)\\ 1.19\\ (0.93\text{-}1.53)\\ 0.98\\ (0.70\text{-}1.36)\\ 0.86\\ (0.70\text{-}1.07)\\ 0.57\\ (0.44\text{-}0.75)\\ 0.75\\ (0.58\text{-}0.98)\\ 0.63\\ (0.52\text{-}0.76) \end{array}$	(1.00-1.34 1.01 (0.77-1.33 1.30 (0.99-1.70 1.17 (0.82-1.65 1.15 (0.91-1.44 0.74 (0.56-0.99 0.84 (0.64-1.11 0.77 (0.63-0.93
$\begin{array}{c} (0.76\text{-}1.27)\\ 0.77\\ (0.57\text{-}1.03)\\ 1.08\\ (0.76\text{-}1.52)\\ 1.07\\ (0.86\text{-}1.34)\\ 0.81\\ (0.62\text{-}1.05)\\ 0.91\\ (0.70\text{-}1.19)\\ \textbf{0.77}\\ \textbf{(0.64\text{-}0.93)}\\ 0.98\\ (0.68\text{-}1.42)\\ 0.93\\ (0.82\text{-}1.06) \end{array}$	$\begin{array}{c} (0.44-0.81)\\ 0.64\\ (0.46-0.89)\\ 0.53\\ (0.34-0.82)\\ 0.57\\ (0.43-0.74)\\ 0.44\\ (0.32-0.61)\\ 0.63\\ (0.46-0.86)\\ 0.83\\ (0.69-1.02)\\ 0.74\\ (0.49-1.11)\\ \end{array}$	(0.60-1.11) 0.70 (0.50-0.98) 0.63 (0.40-0.99) 0.74 (0.57-0.98) 0.57 (0.40-0.79) 0.72 (0.52-0.99) 0.90 (0.74-1.10) 0.88 (0.58-1.34)	$\begin{array}{c} (0.41\text{-}0.77)\\ 0.95\\ (0.70\text{-}1.30)\\ 0.72\\ (0.47\text{-}1.07)\\ 0.63\\ (0.48\text{-}0.82)\\ 0.47\\ (0.34\text{-}0.66)\\ 0.65\\ (0.47\text{-}0.86)\\ 0.71\\ (0.58\text{-}0.88)\\ 0.60\\ \end{array}$	(0.54-1.05) 0.99 (0.72-1.37) 0.85 (0.55-1.30) 0.81 (0.62-1.07) 0.59 (0.41-0.83) 0.71 (0.51-0.99) 0.78 (0.63-0.97) 0.74	(0.42-0.89) 0.92 (0.64-1.32) 0.80 (0.50-1.29) 0.79 (0.58-1.06) 0.60 (0.41-0.87) 0.80 (0.56-1.14) 0.69 (0.54-0.89) 1.04	(0.55-1.19) 0.93 (0.64-1.37) 0.96 (0.59-1.55) 1.00 (0.74-1.37) 0.74 (0.50-1.09) 0.93 (0.65-1.34) 0.74 (0.57-0.97)	0.89 (0.63-1.28) 0.90 (0.60-1.34) 0.74 (0.43-1.26) 0.71 (0.50-0.99) 0.60 (0.40-0.91) 0.71 (0.48-1.07) 0.54 (0.40-0.73)	1.23 (0.85-1.80) 0.94 (0.62-1.42) 0.90 (0.52-1.54) 0.95 (0.67-1.34) 0.77 (0.50-1.18) 0.81 (0.53-1.22) 0.64 (0.47-0.87)	$\begin{array}{c} (0.56-0.94)\\ 1.19\\ (0.93-1.53)\\ 0.98\\ (0.70-1.36)\\ 0.86\\ (0.70-1.07)\\ 0.57\\ (0.44-0.75)\\ 0.75\\ (0.58-0.98)\\ 0.63\\ (0.52-0.76)\\ \end{array}$	(0.77-1.33 1.30 (0.99-1.70 1.17 (0.82-1.65 1.15 (0.91-1.44 0.74 (0.56-0.99 0.84 (0.64-1.11 0.77 (0.63-0.93
$\begin{array}{c} (0.57 - 1.03) \\ 1.08 \\ (0.76 - 1.52) \\ 1.07 \\ (0.86 - 1.34) \\ 0.81 \\ (0.62 - 1.05) \\ 0.91 \\ (0.70 - 1.19) \\ 0.77 \\ (0.64 - 0.93) \\ 0.98 \\ (0.68 - 1.42) \\ 0.93 \\ (0.82 - 1.06) \end{array}$	$\begin{array}{c} (0.46\text{-}0.89)\\ 0.53\\ (0.34\text{-}0.82)\\ 0.57\\ (0.43\text{-}0.74)\\ 0.44\\ (0.32\text{-}0.61)\\ 0.63\\ (0.46\text{-}0.86)\\ 0.83\\ (0.69\text{-}1.02)\\ 0.74\\ (0.49\text{-}1.11) \end{array}$	(0.50-0.98) 0.63 (0.40-0.99) 0.74 (0.57-0.98) 0.57 (0.40-0.79) 0.72 (0.52-0.99) 0.90 (0.74-1.10) 0.88 (0.58-1.34)	$\begin{array}{c} (0.70\text{-}1.30)\\ 0.72\\ (0.47\text{-}1.07)\\ 0.63\\ (0.48\text{-}0.82)\\ 0.47\\ (0.34\text{-}0.66)\\ 0.65\\ (0.47\text{-}0.86)\\ 0.71\\ (0.58\text{-}0.88)\\ 0.60\\ \end{array}$	(0.72-1.37) 0.85 (0.55-1.30) 0.81 (0.62-1.07) 0.59 (0.41-0.83) 0.71 (0.51-0.99) 0.78 (0.63-0.97) 0.74	$\begin{array}{c} (0.64\text{-}1.32)\\ 0.80\\ (0.50\text{-}1.29)\\ 0.79\\ (0.58\text{-}1.06)\\ 0.60\\ (0.41\text{-}0.87)\\ 0.80\\ (0.56\text{-}1.14)\\ 0.69\\ (0.54\text{-}0.89)\\ 1.04 \end{array}$	(0.64-1.37) 0.96 (0.59-1.55) 1.00 (0.74-1.37) 0.74 (0.50-1.09) 0.93 (0.65-1.34) 0.74 (0.57-0.97)	0.90 (0.60-1.34) 0.74 (0.43-1.26) 0.71 (0.50-0.99) 0.60 0.60 0.71 (0.40-0.91 0.71 0.54 (0.40-0.73 (0.40-0.73 (0.40-0.73 (0.40-0.74 (0.40	0.94 (0.62-1.42) 0.90 (0.52-1.54) 0.95 (0.67-1.34) 0.77 (0.50-1.18) 0.81 (0.53-1.22) 0.64 (0.47-0.87)	$\begin{array}{c} (0.93-1.53)\\ 0.98\\ (0.70-1.36)\\ 0.86\\ (0.70-1.07)\\ 0.57\\ (0.44-0.75)\\ 0.75\\ (0.58-0.98)\\ 0.63\\ (0.52-0.76)\\ \end{array}$	(0.99-1.7(1.17 (0.82-1.65 1.15 (0.91-1.44 0.74 0.74 0.84 (0.64-1.11) 0.77 (0.63-0.93
$\begin{array}{c} 1.08 \\ (0.76\text{-}1.52) \\ 1.07 \\ (0.86\text{-}1.34) \\ 0.81 \\ (0.62\text{-}1.05) \\ 0.91 \\ (0.70\text{-}1.19) \\ \textbf{0.77} \\ \textbf{(0.64\text{-}0.93)} \\ 0.98 \\ (0.68\text{-}1.42) \\ 0.93 \\ (0.82\text{-}1.06) \end{array}$	$\begin{array}{c} 0.53 \\ (0.34\text{-}0.82) \\ 0.57 \\ (0.43\text{-}0.74) \\ 0.44 \\ (0.32\text{-}0.61) \\ 0.63 \\ (0.46\text{-}0.86) \\ 0.83 \\ (0.69\text{-}1.02) \\ 0.74 \\ (0.49\text{-}1.11) \end{array}$	0.63 (0.40-0.99) 0.74 (0.57-0.98) 0.57 (0.40-0.79) 0.72 (0.52-0.99) 0.90 (0.74-1.10) 0.88 (0.58-1.34)	$\begin{array}{c} 0.72 \\ (0.47 - 1.07) \\ 0.63 \\ (0.48 - 0.82) \\ 0.47 \\ (0.34 - 0.66) \\ 0.65 \\ (0.47 - 0.86) \\ 0.71 \\ (0.58 - 0.88) \\ 0.60 \end{array}$	0.85 (0.55-1.30) 0.81 (0.62-1.07) 0.59 (0.41-0.83) 0.71 (0.51-0.99) 0.78 (0.63-0.97) 0.74	$\begin{array}{c} 0.80\\ (0.50\text{-}1.29)\\ 0.79\\ (0.58\text{-}1.06)\\ 0.60\\ (0.41\text{-}0.87)\\ 0.80\\ (0.56\text{-}1.14)\\ 0.69\\ (0.54\text{-}0.89)\\ 1.04 \end{array}$	0.96 (0.59-1.55) 1.00 (0.74-1.37) 0.74 (0.50-1.09) 0.93 (0.65-1.34) 0.74 (0.57-0.97)	0.74 (0.43-1.26) 0.71 (0.50-0.999 0.60 0.71 (0.40-0.91 0.71 (0.48-1.07) 0.54 (0.40-0.73)	0.90 0.52-1.54) 0.95 (0.67-1.34) 0.77 (0.50-1.18) 0.81 (0.53-1.22) 0.64 (0.47-0.87)	$\begin{array}{c} 0.98\\ (0.70\text{-}1.36)\\ \hline 0.86\\ (0.70\text{-}1.07)\\ \hline 0.57\\ (0.44\text{-}0.75)\\ \hline 0.75\\ (0.58\text{-}0.98)\\ \hline 0.63\\ (0.52\text{-}0.76) \end{array}$	1.17 (0.82-1.62 1.15 (0.91-1.44 0.74 (0.56-0.99 0.84 (0.64-1.11 0.77 (0.63-0.93
$\begin{array}{c} 1.07 \\ (0.86-1.34) \\ 0.81 \\ (0.62-1.05) \\ 0.91 \\ (0.70-1.19) \\ 0.77 \\ (0.64-0.93) \\ 0.98 \\ (0.68-1.42) \\ 0.93 \\ (0.82-1.06) \end{array}$	$\begin{array}{c} 0.57 \\ (0.43-0.74) \\ 0.44 \\ (0.32-0.61) \\ 0.63 \\ (0.46-0.86) \\ 0.83 \\ (0.69-1.02) \\ 0.74 \\ (0.49-1.11) \end{array}$	0.74 (0.57-0.98) 0.57 (0.40-0.79) 0.72 (0.52-0.99) 0.90 (0.74-1.10) 0.88 (0.58-1.34)	$\begin{array}{c} 0.63 \\ (0.48 \text{-} 0.82) \\ 0.47 \\ (0.34 \text{-} 0.66) \\ 0.65 \\ (0.47 \text{-} 0.86) \\ 0.71 \\ (0.58 \text{-} 0.88) \\ 0.60 \end{array}$	0.81 (0.62-1.07) 0.59 (0.41-0.83) 0.71 (0.51-0.99) 0.78 (0.63-0.97) 0.74	$\begin{array}{c} 0.79\\ (0.58-1.06)\\ 0.60\\ (0.41-0.87)\\ 0.80\\ (0.56-1.14)\\ 0.69\\ (0.54-0.89)\\ 1.04\\ \end{array}$	1.00 (0.74-1.37) 0.74 (0.50-1.09) 0.93 (0.65-1.34) 0.74 (0.57-0.97)	0.71 (0.50-0.99p 0.60 (0.40-0.91p 0.71 (0.48-1.07p 0.54 (0.40-0.73p)	0.95 (0.67-1.34) 0.77 (0.50-1.18) 0.81 (0.53-1.22) 0.64 (0.47-0.87)	$\begin{array}{c} 0.86 \\ (0.70\text{-}1.07) \\ 0.57 \\ (0.44\text{-}0.75) \\ 0.75 \\ (0.58\text{-}0.98) \\ 0.63 \\ (0.52\text{-}0.76) \end{array}$	1.15 (0.91-1.4 0.74 (0.56-0.99 0.84 (0.64-1.1 0.77 (0.63-0.9
0.81 (0.62-1.05) 0.91 (0.70-1.19) 0.77 (0.64-0.93) 0.98 (0.68-1.42) 0.93 (0.82-1.06)	$\begin{array}{c} 0.44 \\ (0.32 - 0.61) \\ 0.63 \\ (0.46 - 0.86) \\ 0.83 \\ (0.69 - 1.02) \\ 0.74 \\ (0.49 - 1.11) \end{array}$	0.57 (0.40-0.79) 0.72 (0.52-0.99) 0.90 (0.74-1.10) 0.88 (0.58-1.34)	$\begin{array}{c} 0.47 \\ (0.34 \text{-} 0.66) \\ 0.65 \\ (0.47 \text{-} 0.86) \\ 0.71 \\ (0.58 \text{-} 0.88) \\ 0.60 \end{array}$	0.59 (0.41-0.83) 0.71 (0.51-0.99) 0.78 (0.63-0.97) 0.74	$\begin{array}{c} 0.60 \\ (0.41 - 0.87) \\ 0.80 \\ (0.56 - 1.14) \\ 0.69 \\ (0.54 - 0.89) \\ 1.04 \end{array}$	0.74 (0.50-1.09) 0.93 (0.65-1.34) 0.74 (0.57-0.97)	0.60 (0.40-0.91) 0.71 (0.48-1.07) 0.54 (0.40-0.73)	0.77 (0.50-1.18) 0.81 (0.53-1.22) 0.64 (0.47-0.87)	$\begin{array}{c} 0.57\\ (0.44\text{-}0.75)\\ 0.75\\ (0.58\text{-}0.98)\\ 0.63\\ (0.52\text{-}0.76)\end{array}$	0.74 (0.56-0.9 0.84 (0.64-1.1 0.77 (0.63-0.9
0.91 (0.70-1.19) 0.77 (0.64-0.93) 0.98 (0.68-1.42) 0.93 (0.82-1.06)	$\begin{array}{r} 0.63 \\ (0.46 - 0.86) \\ 0.83 \\ (0.69 - 1.02) \\ 0.74 \\ (0.49 - 1.11) \end{array}$	0.72 (0.52-0.99) 0.90 (0.74-1.10) 0.88 (0.58-1.34)	0.65 (0.47-0.86) 0.71 (0.58-0.88) 0.60	0.71 (0.51-0.99) 0.78 (0.63-0.97) 0.74	0.80 (0.56-1.14) 0.69 (0.54-0.89) 1.04	0.93 (0.65-1.34) 0.74 (0.57-0.97)	0.71 (0.48-1.07) 0.54 (0.40-0.73)	0.81 (0.53-1.22) 0.64 (0.47-0.87)	0.75 (0.58-0.98) 0.63 (0.52-0.76)	0.84 (0.64-1.1 0.77 (0.63-0.9
0.77 (0.64-0.93) 0.98 (0.68-1.42) 0.93 (0.82-1.06)	0.83 (0.69-1.02) 0.74 (0.49-1.11)	0.90 (0.74-1.10) 0.88 (0.58-1.34)	0.71 (0.58-0.88) 0.60	0.78 (0.63-0.97) 0.74	0.69 (0.54-0.89) 1.04	0.74 (0.57-0.97)	0.54 (0.40-0.73)	0.64 (0.47-0.87)	0.63 (0.52-0.76)	0.77 (0.63-0.9
0.98 (0.68-1.42) 0.93 (0.82-1.06)	0.74 (0.49-1.11)	0.88 (0.58-1.34)	0.60	0.74	1.04					
0.93 (0.82-1.06)			10.30-0.751		(0.66-1.62)	(0.73-1.88)	0.69 (0.39-1.22)	(0.50-1.57)	0.78 (0.54-1.11)	0.90 (0.62-1.3
	(0.73-0.97)	0.91 (0.78-1.05)	0.77 (0.67-0.90)	0.84 (0.72-0.97)	0.69 (0.57-0.82)	0.76 (0.63-0.91)	0.85	0.96	0.79 (0.70-0.90)	0.93 (0.81-1.0
0.94 (0.69-1.28)	0.45 (0.31-0.67)	0.61 (0.41-0.91)	0.68 (0.48-0.97)	0.97 (0.68-1.40)	0.67 (0.44-1.02)	0.89 (0.57-1.37)	0.91	1.33	0.60 (0.44-0.83)	0.82
1.11	$\begin{array}{c} (0.51 - 0.67) \\ 0.77 \\ (0.57 - 1.03) \end{array}$	0.86	$\begin{array}{c} (0.48 - 0.97) \\ 0.92 \\ (0.69 - 1.23) \end{array}$	$\begin{array}{r} (0.08-1.40) \\ 1.13 \\ (0.84-1.52) \end{array}$	1.02	1.15	0.96	1.19	1.10	(0.59-1.1
(0.86-1.43) 1.05	0.93	(0.64-1.17) 0.96	1.05	1.09	(0.74-1.41) 0.93	(0.81-1.62) 0.97	(0.67-1.39) 1.24	1.37	(0.86-1.40) 0.97	(1.06-1.7 1.17
1.04	0.72	0.80	0.98	1.05	1.08	1.20		(1.03-1.81)	1.28	(0.95-1.4
1.13	0.87	0.99	1.24	1.41	1.39	1.59	(0.83-2.10) 1.60	(0.87-2.27) 1.82	1.37	(0.99-1.9 1.51
1.08	1.04	1.10	1.17	1.25	1.12	1.22	1.43 D	(1.28-2.61) 1.55 $(1.25, 1.00)$	1.16	(1.15-1.9
0.93	0.82	1.04	1.02	1.31	1.14	1.43	0.95 b	1.22	1.03	(1.12-1.5
1.14	1.19	1.24	1.42	1.47	1.48	1.55		(0.85-1.77) 1.79	1.69	(1.04-1.7
1.28	1.12	1.25	1.08	1.24	1.10	1.26	1.23 🔒	1.50	1.17	(1.49-2.3 1.53 (1.22-1.9
	$\begin{array}{c} (0.85\text{-}1.29) \\ 1.04 \\ (0.72\text{-}1.49) \\ 1.13 \\ (0.85\text{-}1.51) \\ 1.08 \\ (0.92\text{-}1.25) \\ 0.93 \\ (0.71\text{-}1.21) \\ 1.14 \\ (0.90\text{-}1.43) \end{array}$	$\begin{array}{cccc} (0.85\text{-}1.29) & (0.74\text{-}1.17) \\ \hline 1.04 & 0.72 \\ (0.72\text{-}1.49) & (0.47\text{-}1.10) \\ \hline 1.13 & 0.87 \\ (0.85\text{-}1.51) & (0.63\text{-}1.19) \\ \hline 1.08 & 1.04 \\ (0.92\text{-}1.25) & (0.88\text{-}1.22) \\ \hline 0.93 & 0.82 \\ (0.71\text{-}1.21) & (0.62\text{-}1.07) \\ \hline 1.14 & 1.19 \\ (0.90\text{-}1.43) & (0.93\text{-}1.52) \\ \hline 1.28 & 1.12 \end{array}$	$\begin{array}{c ccccc} (0.85\text{-}1.29) & (0.74\text{-}1.17) & (0.76\text{-}1.21) \\ \hline 1.04 & 0.72 & 0.80 \\ (0.72\text{-}1.49) & (0.47\text{-}1.10) & (0.52\text{-}1.23) \\ \hline 1.13 & 0.87 & 0.99 \\ (0.85\text{-}1.51) & (0.63\text{-}1.19) & (0.71\text{-}1.38) \\ \hline 1.08 & 1.04 & 1.10 \\ (0.92\text{-}1.25) & (0.88\text{-}1.22) & (0.93\text{-}1.30) \\ \hline 0.93 & 0.82 & 1.04 \\ (0.71\text{-}1.21) & (0.62\text{-}1.07) & (0.78\text{-}1.39) \\ \hline 1.14 & 1.19 & 1.24 \\ (0.90\text{-}1.43) & (0.93\text{-}1.52) & (0.96\text{-}1.59) \\ \hline 1.28 & 1.12 & 1.25 \\ \end{array}$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

36/bmjop Abbreviations: CI, Confidence Interval; MSK, Musculoskeletal; OR, Odds Ratio; PA, Physical Activity; WHO, World Health Brganization Footnote: A group of participants who did not meet the WHO recommendations of PA (i.e. PA less than 150 min per week) was set as the reference group. The Lon Tisk. model was adjusted for sex, age, employment status, and depression risk. -059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright.

i able 2.	Associ	ation of PA	A with the N	umper of M	ISK-Pain LO	cations					ر د		
Numbe	or of					Dos	e of WHO Gu	ideline-Base	ed PA	-	ž –		
MSK-H	5	150-300 min		300-450 min		450-600 min		600-750 min		750- 9 00 min		900+ min	
Locati		Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)						
Minim 1 locat		1.06 (0.95-1.18)	1.10 (0.98-1.23)	1.04 (0.93-1.17)	1.12 (0.99-1.27)	1.01 (0.89-1.14)	1.11 (0.98-1.26)	0.92 (0.80-1.06)	1.04 (0.90-1.20)	1.09 (0.80-1.28)	1.28 (1.10-1.51)	1.05 (0.94-1.17)	1.30 (1.16-1.45)
Minim 3 locat		0.89 (0.78-1.01)	0.97 (0.85-1.11)	0.80 (0.70-0.93)	0.90 (0.78-1.04)	0.80 (0.69-0.93)	0.93 (0.80-1.08)	0.86 (0.72-1.02)	1.00 (0.84-1.19)	0.93 (0.77-1.12)	1.12 (0.93-1.36)	0.88 (0.77-0.99)	1.08 (0.94-1.23)
Minim 5 locat		0.76 (0.62-0.93)	0.84 (0.69-1.03)	0.65 (0.51-0.82)	0.75 (0.60-0.95)	0.61 (0.48-0.78)	0.73 (0.57-0.93)	0.74 (0.56-0.97)	0.85 (0.64-1.13)	0.87 <u>(0.66-1.16)</u>	1.09 (0.82-1.45)	0.83 (0.68-1.01)	1.06 (0.87-1.29)
Minim 10 locat		0.70 (0.45-1.07)	0.76 (0.49-1.17)	0.32 (0.17-0.61)	0.36 (0.19-0.68)	0.57 (0.34-0.98)	0.64 (0.37-1.10)	0.64 (0.35-1.19)	0.67 (0.35-1.40)	0.62 (0.31-1.23)	0.70 (0.35-1.40)	0.61 (0.39-0.95)	0.67 (0.42-1.06)

Table ? Association of DA with the Number of MSK Dain I coations

Abbreviations: CI, Confidence Interval; MSK, Musculoskeletal; OR, Odds Ratio; PA, Physical Activity; WHO, World Health Prganization Footnote: A group of participants who did not meet the WHO recommendations of PA (i.e. PA less than 150 min per week) was set as the reference group. The model was adjusted for sex, age, employment status, and depression risk. from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright.

36/bmjopen-20

		BMJ Open	Page
	STR	OBE 2007 (v4) Statement—Checklist of items that should be included in reports of <i>cross-sectional studies</i>	
Section/Topic	ltem #	Recommendation 6	Reported on page #
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used term in the title or the abstract	1-3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was done and what was	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	3-4
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5
Participants	6	(<i>a</i>) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Gige diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-6
Bias	9	Describe any efforts to address potential sources of bias	5-6
Study size	10	Explain how the study size was arrived at	5-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groven and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5-6
		(a) Describe an statistical methods, including those used to control for control nor contro nor control nor control nor control nor control nor control nor c	5-6
		(c) Explain how missing data were addressed	5-6
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
Results		co pyright.	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

 mjopen-2021

by copyright.

		Ī	
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examink for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 않	6
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on കreposures and potential confounders	6
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	7
Main results	16	(<i>a</i>) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-8
		(b) Report category boundaries when continuous variables were categorized	7-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful tin $\check{\Xi}$ period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses $\stackrel{O}{\exists}$	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	8-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-12
Other information		April	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for 韩e original study on which the present article is based	13

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in centrol studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicinegrg/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Association between physical activity and musculoskeletal pain: an analysis of international data from the ASAP survey

Journal:	BMJ Open				
Manuscript ID	omjopen-2021-059525.R1				
Article Type:	Original research				
Date Submitted by the Author:	16-May-2022				
Complete List of Authors:	Rhim, Hye Chang; Metrowest Medical Center Tenforde, Adam; Harvard Medical School, Department of Physical Medicine and Rehabilitation; Spaulding Rehabilitation Hospital Mohr, Lisa; Goethe University Frankfurt, Department of Sports Medicine Hollander, Karsten; MSH Medical School Hamburg, Institute of Interdisciplinary Exercise Science and Sports Medicine Vogt, Lutz; Goethe-Universitat Frankfurt am Main, Department of Sports Medicine Groneberg, David; Goethe University Frankfurt, Institute of Occupational Medicine, Social Medicine and Environmental Medicine Wilke, Jan; Goethe University Frankfurt, Institute of Occupational Medicine, Social Medicine and Environmental Medicine				
Primary Subject Heading :	Sports and exercise medicine				
Secondary Subject Heading:	Epidemiology, Public health, Sports and exercise medicine, Rehabilitation medicine, Rheumatology				
Keywords:	SPORTS MEDICINE, REHABILITATION MEDICINE, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY, PAIN MANAGEMENT				

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

Association between physical activity and musculoskeletal pain: an

analysis of international data from the ASAP survey

Hye Chang Rhim*, Adam Tenforde*, Lisa Mohr, Karsten Hollander, Lutz Vogt, David A.

Groneberg, Jan Wilke⁺

* The first two authors equally contributed to this work

Hye Chang Rhim, MetroWest Medical Center, Tufts University School of Medicine, Framingham, MA, USA

Adam Tenforde, Department of Physical Medicine and Rehabilitation, Harvard Medical School/Spaulding Rehabilitation Hospital, Boston, MA, USA

Lisa Mohr, Department of Sports Medicine, Goethe University Frankfurt, Frankfurt, Germany

Karsten Hollander, Institute of Interdisciplinary Exercise Science and Sports Medicine, Medical School Hamburg, Hamburg, Germany

Lutz Vogt, Department of Sports Medicine, Goethe University Frankfurt, Frankfurt, Germany

David A. Groneberg, Institute of Occupational, Social, and Environmental Medicine, Goethe University, Frankfurt, Germany

Jan Wilke, Institute of Occupational, Social, and Environmental Medicine, Goethe University, Frankfurt, Germany

[‡] Corresponding author: Jan Wilke, Institute of Occupational, Social, and Environmental Medicine, Goethe University, , Frankfurt, Germany, Email: <u>wilke@sport.uni-frankfurt.de</u>

BMJ Open

ABSTRACT

Objective: To investigate the association of physical activity (PA) with musculoskeletal pain (MSK-pain).

Design: Cross-sectional study

Setting: 14 countries (Argentina, Australia, Austria, Brazil, Chile, France, Germany, Italy, the Netherlands, Singapore, South Africa, Spain, Switzerland, and the United States of America)

Participants: Individuals aged 18 or older living in participating countries.

Primary and secondary outcome measures: PA volumes were assessed with an adapted version of the Nordic Physical Activity Questionnaire-short (NPAQ-short). Prevalence of MSK-pain was captured by means of a 20-item checklist of body locations. Based on the WHO recommendation on PA, participants were classified as non-compliers (0-150 min/week), compliers (150-300 min/week), double compliers (300-450 min/week), triple compliers (450-600 min/week), quadruple compliers (600-750 min/week), quintuple compliers (750-900 min/week), and top compliers (more than 900 min/week). Multivariate logistic regression was used to obtain adjusted odds ratios of the association between PA and MSK-pain for each body location, correcting for age, sex, employment status, and depression risk.

Results: A total of 13,741 participants completed the survey. Compared to non-compliers, compliers had smaller odds of MSK-pain in one location (thoracic pain, OR 0.77, CI 0.64-0.93). Double compliance was associated with reduced pain occurrence in six locations (elbow, OR 0.70, CI 0.50-0.98; forearm, OR 0.63, CI 0.40-0.99; wrist, OR 0.74, CI 0.57-0.98; hand, OR 0.57, CI 0.40-0.79; fingers, OR 0.72, CI 0.52-0.99; abdomen, OR 0.61, CI 0.41-0.91). Triple to top compliance was also linked with lower odds of MSK-pain (five locations in triple compliance, three in quadruple compliance, two in quintuple compliance, three in top compliance), but, at the same time, presented increased odds of MSK-pain in some of the other locations.

Conclusion: A dose of 300-450 min WHO-equivalent PA/week was associated with reduced MSK-pain. On the other hand, excessive doses of PA were associated with increased pain in certain body locations.

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

Strengths and Limitations of this study

- This is the first large-scale analysis of associations between MSK pain and PA considering multiple anatomical locations
- Large sample size enabled to investigate the associations between different degrees of compliance to physical activity recommended by WHO and MSK-pain
- Administration of the survey in 14 countries allowed participation of diverse populations

to beet eview only

- Self-reported data may be subject to recall bias
- Cross-sectional observational design prohibits causal inference

INTRODUCTION

Musculoskeletal pain (MSK-pain) is a common condition that can have negative physical, psychological, and social impacts.¹ A summary of previous epidemiological studies conducted with diverse techniques and populations revealed that MSK-pain affects between 13.5% and 47% of the general population with prevalence higher in women and increasing strongly with age.² Musculoskeletal conditions contribute to disability, especially in older age groups.² It has been reported that disability-adjusted life-years (DALYs), which reflects the years of life lost due to premature mortality and years of life lived with disability, increased by 62% between 1990 and 2016 around the world with 20% surge during the ten-year interval from 2006 to 2016.³ Most of the increased burden has derived from disability due to increased aging population affected by MSK conditions, , and the burden of MSK disorders is expected to increase even more in the future.⁴

Achieving sufficient physical activity (PA) is associated with a variety of positive health outcomes such as substantial risk reduction in all-cause mortality⁵ as well as multiple chronic diseases including type 2 diabetes and metabolic syndrome,⁶ cancer,⁶ and cardiovascular disease.⁷ In the light of these positive impacts, World Health Organization (WHO) recommends 150-300 min of moderate-intensity PA, or 75-150 min of vigorous-intensity PA, or aerobic PA with some combination of moderate and vigorous intensities.⁸ PA is also considered one of the most important strategies to prevent and manage MSK pain.⁹ However, compared to the number of studies investigating the association of PA with non-communicable disease, there seems to be a literature gap regarding MSK-pain. Furthermore, it is still less clear whether the amounts recommended by WHO are sufficient to elicit benefits in terms of addressing MSK-pain. The few available studies examining the relation of regular PA and MSK-pain tended to focus on

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

influence of PA for specific body locations or specific diagnoses such as low back pain, neck pain, or osteoarthritis and found inconsistent results.¹⁰ Other studies have evaluated the associations between PA and pain in occupational settings such as among physical therapists or teaching staff.^{11 12} Particularly, the interplay between the volume of PA and MSK-pain within the general population has been less explored.

The purpose of this study was to investigate the association of total PA with MSK-pain in a variety of anatomical locations including both upper and lower extremities. We hypothesize that greater time spent in PA than WHO recommendation would be associated with reduction of MSK-pain, but excess time performing PA might be associated with higher MSK-pain.

METHODS

Study Design

This article presents an explorative analysis of pre-pandemic baseline data on PA and MSK-pain assessed during the ASAP (Activity and Health during the SARS-CoV-2 Pandemic) survey. The survey was administered with results collected between April 3 and May 9, 2020, including participants from 14 countries (Argentina, Australia, Austria, Brazil, Chile, France, Germany, Italy, the Netherlands, Singapore, South Africa, Spain, Switzerland, and the United States of America (USA)).¹³⁻¹⁶ Ethical approval was obtained from the ethics committees of the study center and collaborating institutions. All participants provided digital informed consent.

Participants

Eligibility for participation in the ASAP survey was limited to individuals aged 18 or older living in participating countries. Recruitment was performed online using promotion by

BMJ Open

health-related organizations, mailing lists, and social media advertising (e.g. Facebook, Instagram, Twitter).

Questionnaire

To capture PA, the ASAP survey incorporated an adapted version of the Nordic Physical Activity Questionnaire-short (NPAQ-short). The instrument retrospectively assessed the amounts of moderate and combined moderate and vigorous activities (min/week) during leisure and occupational time. Moderate activities were defined as those that increase heart rate or breathing, and vigorous activities were defined as those that make heart racing, sweating, and shortness of breath. The questionnaire asked how much time participants spent in total on both moderate and vigorous PA on a typical week, and the time spent in all activities with a minimal duration of 10 minutes was asked to be added and entered in the form. The NPAQ-short has been shown to be reliable (test-retest reliability: rho = 0.80 to 0.82) and valid for observing compliance with the WHO recommendations on PA.¹⁷ The questionnaire was available in 7 different languages (Dutch, English, German, French, Italian, Brazilian-Portuguese, Spanish), and clarity and comprehensibility were validated by native speakers through forward and backward translation.

Prevalence of MSK-pain was captured by means of binary responses (yes/no) to an adapted 20-item checklist from a consensus statement on epidemiological injury reporting.¹⁸ Body locations were categorized as follows: neck/cervical spine, shoulder, upper arm, elbow, forearm, wrist, hand, fingers, thoracic spine, ribs, lower back, abdomen, pelvis/gluteal, hip, groin, thigh, knee, lower leg, ankle/Achilles tendon, foot/toe.

The English version of the ASAP survey can be found in Supplemental File 1.

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

Data Processing and Statistical Analysis

Self-reported PA was categorized as multiples of compliance with WHO guidelines which recommend 150-300 minutes/week of moderate activity, 75-150 minutes/week of vigorous activity, or any adequate combination of both.⁸ We used the formula (minutes of moderate-to-vigorous PA – minutes of vigorous PA) + minutes of vigorous PA *2 to classify participants as non-compliers (0-150 min/week), compliers (150-300 min/week), double compliers (300-450 min/week), triple compliers (450-600 min/week), quadruple compliers (600-750 min/week), quintuple compliers (750-900 min/week), and top compliers (more than 900 min/week).

For each body region, univariate logistic regression was conducted to calculate the unadjusted odds ratio (OR) of the association between pain (dependent variable) and PA. In a similar way, univariate logistic regression was then used to identify associations of pain (dependent variable) and potential confounding variables (sex, age, employment status, depression risk). Finally, multivariate logistic regression was performed including these confounding variables (if relevant) to obtain the adjusted ORs and 95% confidence interval (CI) of the association between the volume of PA and pain. All data analyses were conducted using SPSS 22 (SPSS INC., Armonk, NY, USA), and the significance level was set to $\alpha = 0.05$.

Patient and Public Involvement

Members of the target population without medical background were involved in the designing phase of the ASAP questionnaire. The questionnaire was face validated for each

BMJ Open

RESULTS

Valid datasets were identified for 13,741 participants (38 ± 15 years, minimum 18 and maximum 100, 59% females). The demographic data are summarized in the Table 1. 2604 individuals did not meet the WHO recommendation of PA while n=2735 belonged to 150-300 min group, n=1957 to 300-450 min group, n=1749 to 450-600 min group, n=1066 to 600-750 min group, n=849 to 750-900 min group, and n=2781 to 900+ min group. Comprehensive results are summarized in the Table 2 and 3.

Compared to inactive individuals, simple compliance was associated with reduced MSKpain in one body location (thoracic pain, OR 0.77, CI 0.64-0.93 Table 1). Double compliance increased the number of locations with less pain to six (elbow, OR 0.70, CI 0.50-0.98; forearm, OR 0.63, CI 0.40-0.99; wrist, OR 0.74, CI 0.7-0.98; hand, OR 0.57, CI 0.40-0.79; fingers, OR 0.72, CI 0.52-0.99; abdomen, OR 0.61, CI 0.41-0.91). Although higher amounts of PA were linked to lower pain levels to a variable degree (five body locations in triple compliance, three in quadruple compliance, two in quintuple compliance, three in top compliance), they also showed increased pain in other locations. Specifically, triple compliance was associated with higher pain in thigh (OR 1.41, CI 1.03-1.92), knee (OR 1.25, CI 1.06-1.50), and ankle/Achilles tendon (OR 1.47, CI 1.14-1.88). Quadruple compliance increased pain locations to four, quintuple compliance to six, and top compliance to seven.

Triple compliance was associated with lower odds to have a total of 5 or more (OR 0.75, CI 0.60-0.95) or 10 or more (OR 0.36, CI 0.19-0.68) pain locations, and quadruple compliance

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

was associated with lower odds to have 5 or more pain locations (OR 0.73, CI 0.57-0.93). However, quintuple and top compliances were associated with higher odds of having a minimum one pain location (OR 1.28, CI 1.10-1.51 and 1.30, CI 1.16-1.45 respectively).

DISCUSSION

The purpose of the present study was to understand the relation between PA and MSKpain. Previous research focused on the impact of PA on specific locations of MSK-pain (e.g., low back and neck¹⁹) or certain occupational settings.^{11 12} Our large-scale multinational study is novel in that it identified the associations between different degrees of compliance to PA recommended by WHO and multiple body locations in the general population after adjusting for multiple cofounding factors including age, which is known to be positively associated with MSK-pain prevalence.

Guideline compliance (150-300 min per week) was weakly associated with MSK pain, showing lower odds of having pain only in thoracic spine but higher odds in foot/toes. In contrast, double compliance (300-450 min per week) substantially increased the number of beneficial associations to six and thus seems to represent the optimal dose when PA is undertaken to prevent MSK. Finally, higher levels of PA (triple to top compliance) were associated with less odds of having pain in multiple upper body locations but paradoxically contributed to higher odds of lower extremity pain. Notably, participating in 300-600 min of PA per week was associated with lower odds of having pain in upper extremities, neck, and thoracic and lumbar spine. In contrast, participating in greater than 450 min of PA per week was associated with higher odds of having pain in the lower extremity.

BMJ Open

2	
3	
4	
4	
5	
6	
7	
8	
•	
9	
10	
11	
12	
14	
15	
16	
17	
18	
19	
20	
21	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
34 35	
34 35 36	
34 35	
34 35 36 37	
34 35 36 37 38	
34 35 36 37 38 39	
34 35 36 37 38 39 40	
34 35 36 37 38 39 40 41	
34 35 36 37 38 39 40 41	
34 35 36 37 38 39 40 41 42	
34 35 36 37 38 39 40 41 42 43	
34 35 36 37 38 39 40 41 42 43 44	
 34 35 36 37 38 39 40 41 42 43 44 45 	
 34 35 36 37 38 39 40 41 42 43 44 45 46 	
 34 35 36 37 38 39 40 41 42 43 44 45 46 	
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 	
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 	
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 	
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 	
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 	
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 	
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 	
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 	
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 	
34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	
3435363738394041424344454445464748505152535455	
343536373839404142434445464748495051525354	
343536373839404142434445444546474849505152545557	
34 35 36 37 38 39 40 41 23 44 45 46 47 48 9 51 52 53 45 56 57 58	
343536373839404142434445444546474849505152545557	

Time spent in PA and pain in neck, back, and upper extremity

A previous systematic review showed that there was limited evidence for no association between PA and neck pain.¹⁹ However, our study found that participating in PA between 450-900+ min was associated with lower odds of having pain in neck/cervical spine. Several epidemiological studies have demonstrated that certain postures sustained for prolonged duration combined with sedentary lifestyle were associated with neck pain.²⁰⁻²² Therefore, increased PA levels may be helpful to consider in those at risk for neck pain.

Association between PA and thoracic spine has been less explored,²³ but a recent observational study found that PA less than 150 min per week was associated with reduced thoracic mobility.²⁴ Our findings build on previous research in that PA less than 150 min per week is also associated with higher odds of having pain in the thoracic spine.

While it is generally accepted that PA and exercise are beneficial in the management of acute and chronic low back pain, a previous systematic review could not identify either positive or negative relationship.²⁵ One study suggested that the relationship between the level of activity and back pain might be explained by a U-shaped curve that suggests both low and excessive PA may increase the risk of low back pain.²⁶ Our findings partly support this concept as PA of 450-750 min was associated with lower odds of low back pain while lower or higher PA than that range did not have significant association.

PA in the range of 300-600 min was also associated with lower odds of having pain in several locations in the upper extremity such as elbow, forearm, wrist, hand, and fingers. PA exceeding 750 min was associated with higher odds of shoulder pain. The underlying mechanisms of how PA modulates pain are not completely understood, but several pathways have been proposed. Animal study findings suggest regular PA may act on the central nervous

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

system (CNS) and alter rate of pain hypersensitivity, dysregulation of pain modulation, and development of chronic pain.²⁷⁻²⁹ In humans, it has been proposed that PA may intervene excitability and inhibition in the CNS,³⁰⁻³² and anti-inflammatory and antioxidant effects of regular PA might diminish the processes contributing to central sensitization.³³⁻³⁵ Other proposed mechanisms in humans include the activation of opioid and serotonin pathways³⁶ or involvement of endocannabinoid system³⁷ induced from regular PA which could exert analgesic effects. While further research is needed to elucidate how much and what type of PA can induce such changes to modulate pain, our results suggest that PA between 300-600 mins per week may be sufficient for spinal conditions and upper extremity pain, with PA exceeding 750 min associated with higher likelihood of shoulder pain.

Association of PA and lower extremity pain

The association of PA to lower extremity pain was different than what was observed for upper extremity and spine conditions. Our results suggest PA exceeding 450 min was associated with higher odds of MSK-pain in lower extremity. These findings may be partially explained by higher amounts of PA are likely to involve greater use of the lower extremity. In the United States, it has been reported that walking is the most popular form of exercise followed by biking, yard work, strength training, dancing, and running, which are activities that commonly place physical demands through the lower extremity.³⁸ Running is one of the most popular exercises in the world and has been shown to result in lower extremity pain in multiple anatomical locations with nearly all (94.7% of runners) reporting experience of pain at least once after running.³⁹

We also observed that greater PA was associated with a higher number of sites of MSKpain in the lower extremity. A dose response was observed: 450-600 min was associated with

pain in three anatomical regions, 600-750 min with pain in four anatomical regions, 750-900 min with five anatomical regions, and 900+ min with six anatomical regions. The optimal PA level to reduce pain in those with existing musculoskeletal lower extremity pain is unknown. A prior study reported that a minimum of 45 total moderate-vigorous min per week was sufficient to elicit improved or sustained high function with lower-extremity symptoms regardless of age, gender, body mass index, or presence of knee osteoarthritis.⁴⁰ Our findings of PA ranging from 150-450 min not increasing the odds of having pain in the lower extremities suggest this range might be appropriate to be safe and promote other health benefits.

Clinical implication

While the WHO 2020 guidelines on PA recommend 150-300 min of moderate-intensity PA, or 75-150 min of vigorous-intensity PA, or some equivalent combination of moderateintensity and vigorous-intensity aerobic PA per week for optimal health outcomes,⁸ the current study suggests that more PA beyond the WHO recommendation may be necessary to decrease the odds of having pain particularly in the upper extremity. Our findings suggest a target of 300-450 min of PA per week could be optimal for preventing pain in the upper extremity without clear associated higher rate of lower extremity pain. Also, this range was associated with lower odds of having pain in multiple number of locations. Recognizing concerns on higher prevalence of pain in low back, neck, and thoracic spine increased during the COVID-19 pandemic,¹⁵ PA target of the higher target of 450 min of PA may not be advisable for those with increased concern for lower extremity pain. Furthermore, PA above 750 minutes was associated with having at least one pain location. BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

BMJ Open

Limitation

While our findings derived from a large-scale multinational study of participants, we do note potential limitations. Self-report of PA and MSK-pain are limited by reporting bias and inaccuracy including risk for over-reporting level of PA.^{41 42} The cross-sectional study design limits our understanding between PA and the etiology of MSK-pain. Also, we are limited in ability in discriminating the types of PA to report of MSK-pain by anatomical locations. We were not able to distinguish or identify bilateral MSK-pain from our questionnaire as well. Furthermore, because a separate analysis was run for each body region, there is a risk of multiple testing problem. Since our analysis was explorative in nature, further prospective cohort or interventional studies are needed to elucidate the best form and dose of PA to address MSK-pain by anatomical location and specific musculoskeletal injury, and additionally investigate the role of MSK-pain intensity instead of using a binary (yes/no) classification.

CONCLUSION

Our findings showed that PA time above the WHO recommendations was associated with lower odds of having pain in multiple locations such as neck, thoracic spine, low back, and in the upper extremities. Especially, undertaking PA for 300-450 min per week was associated with reduced pain occurrence in six locations, elbow, forearm, wrist, hand, fingers, and abdomen.

Acknowledgment: The authors acknowledge the valuable help from the following authors with promoting ASAP survey for data collection (in alphabetical order): Benedict Tan, Bernhard Novak, Celso Ramiréz, Chiara Fossati, Christoph Heidt, Daniel E. Lieberman, David Jimenez-Pavon, Evert Verhagen, Fabio Pigozzi, Falk Richter, Fernando Laíño, Johannes Jaunig, Julian David Pillay, Luiz Carlos Hespanhol Junior, Marcela González-Gross, Matteo Sattler, Mireille van Poppel, Pascal Edouard, Steffen Willwacher

Funding: This research received no external funding.

Data Availability Statement: Data are available upon reasonable request

Ethics Statements

-Ethics approval: This study was approved by the University of Queensland Health and Behavioural Sciences, Low & Negligible Risk Ethics Sub-Committee, Ethics Committee of Karl Franzens University Graz, Research Ethics Committee of Fundación Instituto Superior de Ciencias de la Salud, Research Ethics Committee of the Universidade Cidade de São Paulo, Institutional Ethics Committee of the University of Santiago de Chile, Saint-Etienne University Hospital Ethical Committee, Ethics Committee of the Faculty of Psychology and Sports Sciences of Goethe University, Comitato di Ateneo per la Ricerca, Università degli Studi di Roma "Foro Italico", Medical Ethical Committee of Amsterdam UMC, Institutional Research Ethics Committee of Durban University of Technology, SingHealth Centralised Institutional Review Board, Cantonal Ethics Committee Northwest Switzerland, Ethics Committee of Universidad Politécnica de Madrid, and Partners Human Research Committee

-Digital informed consent was obtained from all subjects involved in the study.

Authors Contribution: HCR/AT: data collection, interpretation, drafting and critical revision of the manuscript, LM, KH, LV, DG: data collection, critical revision of the manuscript, JW: conception/design, data collection, interpretation, critical revision of the manuscript

Competing interests: None declared.

REFERENCES

15
the COVID-19 pandemic: results from the ASAP survey. <i>Front Med</i> 2021;8:246.
2021;18(5):2235. 16. Wilke J, Hollander K, Mohr L, et al. Drastic reductions in mental well-being observed globally during
substantially decreased in countries affected by COVID-19. Int J Environ Res Public Health
<i>Health</i> 2020;17(18):6515. 15. Wilke J, Mohr L, Tenforde AS, et al. A pandemic within the pandemic? Physical activity levels
14. Wilke J, Mohr L, Tenforde AS, et al. Restrictercise! Preferences regarding digital home training programs during confinements associated with the COVID-19 pandemic. <i>Int J Environ Res Public</i>
 Wilke J, Mohr L, Tenforde AS, et al. Activity and health during the SARS-CoV2 pandemic (ASAP): study protocol for a multi-national network trial. <i>Front Med</i> 2020;7:302.
the Teaching Staff of the University of Douala, Cameroon: Association with Physical Activity Practice. <i>Int J Environ Res Public Health</i> 2021;18(11):6004.
Am J Health Promot 2020;34(1):67-70. 12. Tami AM, Bika Lele EC, Mekoulou Ndongo J, et al. Epidemiology of Musculoskeletal Disorders among
11. Ezzatvar Y, Calatayud J, Andersen L, et al. Are moderate and vigorous leisure-time physical activity associated with musculoskeletal pain? a cross-sectional study among 981 physical therapists.
overview of Cochrane Reviews. Cochrane Database Syst Rev 2017(4)
[published Online First: 2020/06/27] 10. Geneen LJ, Moore RA, Clarke C, et al. Physical activity and exercise for chronic pain in adults: an
9. Lin I, Wiles L, Waller R, et al. Patient-centred care: the cornerstone for high-value musculoskeletal pain management. <i>Br J Sports Med</i> 2020;54(21):1240-42. doi: 10.1136/bjsports-2019-101918
 Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. <i>Br J Sports Med</i> 2020;54(24):1451-62.
diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose- response meta-analysis for the Global Burden of Disease Study 2013. <i>BMJ</i> 2016;354
7. Kyu HH, Bachman VF, Alexander LT, et al. Physical activity and risk of breast cancer, colon cancer,
6. Lee I-M, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. <i>Lancet</i> 2012;380(9838):219-29.
measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. <i>BMJ</i> 2019;366
10.1136/annrheumdis-2013-204680 [published Online First: 2014/03/05] 5. Ekelund U, Tarp J, Steene-Johannessen J, et al. Dose-response associations between accelerometry
4. Smith E, Hoy DG, Cross M, et al. The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study. <i>Ann Rheum Dis</i> 2014;73(8):1462-9. doi:
2017;390(10100):1260-344. doi: 10.1016/s0140-6736(17)32130-x [published Online First: 2017/09/19]
diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990- 2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i>
Rheumatol 2011;25(2):173-83. 3. Collaborators GDaH. Global, regional, and national disability-adjusted life-years (DALYs) for 333
2. Cimmino MA, Ferrone C, Cutolo M. Epidemiology of chronic musculoskeletal pain. Best Pract Res Clin
 Paananen M, Taimela S, Auvinen J, et al. Impact of self-reported musculoskeletal pain on health- related quality of life among young adults. <i>Pain Med</i> 2011;12(1):9-17.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 17 of 34

BMJ Open

17. Danquah IH, Petersen CB, Skov SS, et al. Validation of the NPAQ-short–a brief questionnaire to monitor physical activity and compliance with the WHO recommendations. BMC Public Health 2018;18(1):1-10.
18. Bahr R, Clarsen B, Derman W, et al. International Olympic Committee consensus statement: methods
for recording and reporting of epidemiological data on injury and illness in sports 2020
(including the STROBE extension for sports injury and illness surveillance (STROBE-SIIS)). Orthop
J Sports Med 2020;8(2):2325967120902908.
19. Sitthipornvorakul E, Janwantanakul P, Purepong N, et al. The association between physical activity
and neck and low back pain: a systematic review. <i>Eur Spine J</i> 2011;20(5):677-89.
20. Ortiz-Hernández L, Tamez-González S, Martínez-Alcántara S, et al. Computer use increases the risk of
musculoskeletal disorders among newspaper office workers. Arch Med Res 2003;34(4):331-42.
21. Janwantanakul P, Pensri P, Jiamjarasrangsi W, et al. Associations between prevalence of self-
reported musculoskeletal symptoms of the spine and biopsychosocial factors among office
workers. <i>J Occup Health</i> 2009:0901270054-54.
22. Cagnie B, Danneels L, Van Tiggelen D, et al. Individual and work related risk factors for neck pain
among office workers: a cross sectional study. <i>Eur Spine J</i> 2007;16(5):679-86.
23. Briggs AM, Smith AJ, Straker LM, et al. Thoracic spine pain in the general population: prevalence,
incidence and associated factors in children, adolescents and adults. A systematic review. BMC
Musculoskelet Disord 2009;10(1):1-12.
24. Heneghan NR, Baker G, Thomas K, et al. What is the effect of prolonged sitting and physical activity
on thoracic spine mobility? An observational study of young adults in a UK university setting. BMJ Open 2018;8(5):e019371.
25. Hendrick P, Milosavljevic S, Hale L, et al. The relationship between physical activity and low back pain
outcomes: a systematic review of observational studies. <i>Eur Spine J</i> 2011;20(3):464-74.
26. Heneweer H, Vanhees L, Picavet HSJ. Physical activity and low back pain: a U-shaped relation? <i>Pain</i>
2009;143(1-2):21-25.
27. Bobinski F, Ferreira TAA, Córdova MM, et al. Role of brainstem serotonin in analgesia produced by
low-intensity exercise on neuropathic pain following sciatic nerve injury in mice. Pain
2015;156(12):2595.
28. Sluka KA, O'Donnell JM, Danielson J, et al. Regular physical activity prevents development of chronic
pain and activation of central neurons. <i>J Appl Physiol</i> 2013;114(6):725-33.
29. Stagg NJ, Mata HP, Ibrahim MM, et al. Regular exercise reverses sensory hypersensitivity in a rat
neuropathic pain model: role of endogenous opioids. <i>Anesthesiology</i> 2011;114(4):940-48.
30. Geva N, Defrin R. Enhanced pain modulation among triathletes: a possible explanation for their
exceptional capabilities. <i>Pain</i> 2013;154(11):2317-23. 31. Naugle KM, Ohlman T, Naugle KE, et al. Physical activity behavior predicts endogenous pain
modulation in older adults. Pain 2017;158(3):383-90.
32. Naugle KM, Riley JL. Self-reported physical activity predicts pain inhibitory and facilitatory function.
Med Sci Sports Exerc 2014;46(3):622.
33. Radak Z, Chung HY, Koltai E, et al. Exercise, oxidative stress and hormesis. Ageing Res Rev
2008;7(1):34-42.
34. Woods JA, Wilund KR, Martin SA, et al. Exercise, inflammation and aging. Aging Dis 2012;3(1):130.
35. Dhondt E, Danneels L, Van Oosterwijck S, et al. The influence of physical activity on the nociceptive
flexion reflex in healthy people. <i>Eur J Pain</i> 2021;25(4):774-89.
36. Tour J, Löfgren M, Mannerkorpi K, et al. Gene-to-gene interactions regulate endogenous pain
modulation in fibromyalgia patients and healthy controls-antagonistic effects between opioid
and serotonin-related genes. Pain 2017;158(7):1194-203. doi:
10.1097/j.pain.0000000000000896 [published Online First: 2017/03/11]
16
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

- 37. Tantimonaco M, Ceci R, Sabatini S, et al. Physical activity and the endocannabinoid system: an overview. Cell Mol Life Sci 2014;71(14):2681-98.
- 38. Ham SA, Kruger J, Tudor-Locke C. Participation by US adults in sports, exercise, and recreational physical activities. J Phys Act Health 2009;6(1):6-14.
- 39. Rhim HC, Kim SJ, Jeon JS, et al. Prevalence and risk factors of running-related injuries in Korean nonelite runners: a cross-sectional survey study. J Sports Med Phys Fitness 2021;61(3):413-19. doi: 10.23736/s0022-4707.20.11223-4 [published Online First: 2020/08/04]
- 40. Dunlop DD, Song J, Lee J, et al. Physical activity minimum threshold predicting improved function in adults with Lower-Extremity symptoms. Arthritis Care Res 2017;69(4):475-83.
- 41. Valanou E, Bamia C, Trichopoulou A. Methodology of physical-activity and energy-expenditure assessment: a review. J Public Health 2006;14(2):58-65.
- /iew. .. Patient r.. Jutcomes Res. 2u. 42. Schmier J, Halpern M. Patient recall and recall bias of health state and health status. Expert Rev Pharmacoecon Outcomes Res. 2004; 4 (2): 159–63.

Table 1. Demographic data of the participants by countries

Page 19 of 34							BMJ Open						36/bmjo				
ographie	c data of	f the part	ticipants	by count	tries							pen-20					
ARG	AUS	AUT	BRA	СНЕ	CHL	DEU	ESP	FRA	ITA	NLD	SGP		ZAF	Others	Total		
429/494	56/248	192/546	620/948	115/212	471/766	696/1356	310/277	1200/1046	348/453	50/129	437/434	364/711	236/293	108/122	5632/8035		
37.1 (15.4)	41.6 (14.1)	27.3 (9.6)	34.2 (10.6)	37.3 (11.5)	31.5 (13.6)	40.4 (16.3)	43.0 (13.4)	43.3 (16.9)	38.5 (15.3)	47.5 (14.0)	40.1 (12.1)	₫43.1 <u></u> <u></u>	32.4 (14.3)	40.0 (13.5)	38.3 (15.1)		
54.3 (17.8)	50.1 (14.8)	55.0 (16.5)	53.0 (16.0)	50.4 (15.2)	54.7 (18.2)	52.9 (17.0)	49.2 (15.8)	48.3 (14.8)	56.3 (17.3)	49.0 (14.7)	52.2 (17.6)	149.4 14.9)	52.2 (21.1)	51.2 (17.2)	52.0 (16.8)		
61.9	86.8	62.7	78.8	96.0	59.2	73.2	79.8	69.9	65.9%	77.1	88.8	2084.1	53.7	85.0	72.8		
488.7 (596.2)	352.3 (340.0)	384.6 (408.7)	396.4 (454.9)	379.0 (458.1)	385.7 (518.3)	438.6 (481.3)	493.2 (617.0)	527.9 (516.0)	566.2 (635.3)	506.5 (420.5)	376.5 (445.7)	5401.0 §348.0)	310.6 (455.8)	437.8 (529.7)	439.5 (498.7)		
218.7 (338.0)	121.3 (152.4)	141.4 (206.5)	202.0 (305.7)	130.6 (152.6)	153.9 (287.9)	146.9 (226.5)	188.4 (295.2)	234.7 (343.3)	247.2 (350.1)	200.2 (225.7)	171.0 (302.4)	a 195.9 (230.0)	144.1 (272.7)	203 (275.6)	186.4 (288.8)		
	ARG 429/494 37.1 (15.4) 54.3 (17.8) 61.9 488.7 (596.2) 218.7	ARG AUS 429/494 56/248 37.1 41.6 (15.4) (14.1) 54.3 50.1 (17.8) 86.8 488.7 352.3 (596.2) (340.0) 218.7 121.3	ARG AUS AUT 429/494 56/248 192/546 37.1 41.6 27.3 (15.4) (14.1) (9.6) 54.3 50.1 55.0 (17.8) (14.8) (16.5) 61.9 86.8 62.7 488.7 352.3 384.6 (596.2) (240.0) (408.7) 218.7 121.3 141.4	ARG AUS AUT BRA 429/494 56/248 192/546 620/948 37.1 41.6 27.3 34.2 (15.4) (14.1) (9.6) (10.6) 54.3 50.1 55.0 53.0 (17.8) (14.8) (16.5) 16.0) 61.9 86.8 62.7 78.8 488.7 352.3 384.6 396.4 (596.2) (340.0) 448.7 202.0	ARG AUS AUT BRA CHE 429/494 56/248 192/546 620/948 115/212 37.1 41.6 27.3 34.2 37.3 (15.4) (14.1) (9.6) (10.6) (11.5) 54.3 50.1 55.0 53.0 50.4 (17.8) (14.8) (16.5) 16.0) (15.2) 61.9 86.8 62.7 78.8 96.0 488.7 352.3 384.6 396.4 379.0 (596.2) (340.0) (408.7) (454.9) (458.1) 218.7 121.3 141.4 202.0 130.6	429/49456/248192/546620/948115/212471/76637.1 (15.4)41.6 (14.1)27.3 (9.6)34.2 (10.6)37.3 (11.5)31.5 (13.6)54.3 (17.8)50.1 (14.8)55.0 (16.5)53.0 (16.0)50.4 (15.2)54.7 (18.2)61.986.862.778.8 (408.7)96.059.2488.7 (596.2)352.3 (340.0)384.6 (408.7)396.4 (454.9)379.0 (458.1)385.7 (518.3)218.7121.3141.4202.0130.6153.9	ARG AUS AUT BRA CHE CHL DEU429/49456/248192/546620/948115/212471/766696/135637.141.627.334.237.331.540.4(15.4)(14.1)(9.6)(10.6)(11.5)(13.6)(16.3)54.350.155.053.050.454.752.9(17.8)(14.8)(16.5)(16.0)(15.2)(18.2)(17.0)61.986.862.778.896.059.273.2488.7352.3384.6396.4379.0385.7438.6(596.2)(340.0)(408.7)(454.9)(458.1)(518.3)(481.3)218.7121.3141.4202.0130.6153.9146.9	ARGAUSAUTBRACHECHLDEUESP429/49456/248192/546620/948115/212471/766696/1356310/27737.141.627.334.237.331.540.443.0(15.4)(14.1)(9.6)(10.6)(11.5)(13.6)(16.3)(13.4)54.350.155.053.050.454.752.949.2(17.8)(14.8)(16.5)(16.0)(15.2)(18.2)(17.0)(15.8)61.986.862.778.896.059.273.279.8488.7352.3384.6396.4379.0385.7438.6493.2(596.2)(340.0)(408.7)(454.9)(458.1)(518.3)(461.3)(617.0)218.7121.3141.4202.0130.6153.9146.9188.4	Area of the participants by countriesARGAUSAUTBRACHECHLDEUESPFRA429/49456/248192/546620/948115/212471/766696/1356310/2771200/104637.141.627.334.237.331.540.443.043.3(15.4)(14.1)(9.6)(10.6)(11.5)(13.6)(16.3)(13.4)43.3(17.8)50.155.053.050.454.752.949.248.3(17.8)(14.8)(16.5)(16.0)(15.2)(18.2)(17.0)(15.8)(14.8)61.986.862.778.896.059.273.279.869.9488.7352.3384.6396.4379.0385.7438.6493.2527.9(596.2)(340.0)(408.7)(454.9)(458.1)(518.3)446.9(617.0)(516.0)218.7121.3141.4202.0130.6153.9146.9188.4234.7	ARG AUS AUT BRA CHE CHL DEU ESP FRA ITA429/49456/248192/546620/948115/212471/766696/1356310/2771200/1046348/45337.141.627.334.237.331.540.443.043.338.5(15.4)(14.1)29.6(10.6)(11.5)(13.6)40.4(13.4)43.338.5(15.4)(14.1)25.053.050.454.752.949.248.356.3(17.8)(14.8)(16.5)16.0(15.2)18.2)(17.0)(15.8)14.8)56.361.986.862.778.896.059.273.279.869.965.9%488.7352.3384.6396.4379.0385.7438.6493.2527.9566.2(596.2)121.3141.4202.0130.6153.9146.9188.4234.7247.2	Aus Aus Aut BRA CHE CHL DEU ESP FRA ITA NLD429/49456/248192/546620/948115/212471/766696/1356310/2771200/1046348/45350/12937.141.627.334.237.331.540.443.043.338.547.5(15.4)(14.1)(9.6)(10.6)(11.5)(13.6)(16.3)(13.4)41.656.3(15.3)49.054.350.155.053.050.454.752.949.248.356.3(14.9)61.986.862.778.896.059.273.279.869.965.9%77.1488.7352.3384.6396.4379.0385.7438.6493.2527.9566.2506.5218.7121.3141.4202.0130.6153.9146.9188.4234.7247.2200.2	Area bars by countriesARGAUSAUTBRACHECHLDEUESPFRAITANLDSGP429/49456/248192/546620/948115/212471/766696/1356310/2771200/1046348/45350/129437/43437.141.627.334.237.331.540.443.0(13.4)43.338.5(15.3)40.1(15.4)(14.1)29.6053.050.454.752.949.248.356.349.052.2(17.8)50.155.053.050.4(15.2)(18.2)(17.0)(15.8)41.8)17.3)41.627.321.761.986.862.778.896.059.273.279.869.965.9%77.188.8488.7352.3384.6396.4379.0385.7438.6493.2527.9566.2506.5376.5218.7121.3141.4202.0130.6153.9146.9188.4234.7247.2200.2171.0	Bind OpenBind OpenBind OpenBind OpenBind OpenARGAUSAUTBRACHECHLDEUESPFRAITANLDSGPGUSA429/49456/248192/546620/948115/212471/766696/1356310/2771200/1046348/45350/129437/434G4/71137.141.627.334.237.331.540.443.043.338.547.540.1G4/71137.1(14.1)(9.6)(10.6)(11.5)(13.6)(16.3)(16.3)(16.9)(15.3)44.443.043.338.547.540.1G4/71154.350.155.053.050.454.752.949.248.356.349.052.2649.4(17.8)(14.8)(16.5)(16.0)(15.2)(18.2)(17.0)(15.8)(14.8)(17.3)(14.7)52.2649.461.986.862.778.896.059.273.279.869.965.9%77.188.854.1488.7352.3384.6379.0375.0(518.3)(48.13)(617.0)(516.0)(53.5)50.5376.5601.0218.7121.3141.4202.0130.6153.9146.9188.4234.7247.2200.2171.0649.5	Bind OpenBind OpenBind OpenBind OpenARGAUSAUTBRACHECHLDEUESPFRAITANLDSGPGg/SAZAF429/49456/248192/546620/948115/212471/766696/1356310/2771200/1046348/45350/129437/434694/711236/29337.141.627.334.237.331.540.443.043.338.547.540.1643.132.4(15.4)(14.1)(9.6)(10.6)(11.5)(13.6)(16.3)(13.4)(16.9)(15.3)(14.0)(12.1)64.3.132.4(17.8)(14.8)55.053.050.454.752.949.248.356.349.052.264.421.161.986.862.778.896.059.273.279.869.965.9%77.188.8§8.4.153.7488.7352.3384.6396.4379.0385.7438.6493.2516.0566.2506.5376.5§4.0.1\$310.6218.7121.3141.4202.0130.6153.9146.9188.4234.7247.2200.2171.0695.9144.1	Biological		

Abbreviations: F, Female; M, Male; MVPA, Moderate to Vigorous Physical Activity; SD, Standard Deviation; VPA, Vigorous Physical Activity, WHO-5, The 5item World Health Organization Well-Being Index

Country Abbreviations: ARG, Argentina; AUS, Australia; AUT, Austria; BRA, Brazil; CHE, Switzerland; CHL, Chile; DEU, Germany; ESP, Spain; FRA, France; ITA, Italy; NLD, Netherlands; SGP, Singapore; USA, United States of America; ZAF, South Africa

bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright.

Table 2. Association of PA with MSK-Pain by Anatomical Locations

Dose of WHO Guideline-Based PA									221			
Location of	150-3	00 min	300-4	50 min	450-600 min		r	50 min	7508	00 min	900+ min	
MSK-Pain	Crude OR	Adjusted OR	Crude OR	Adjusted OR	Crude OR	Adjusted OR	Crude OR	Adjusted OR	Crude ORN		Crude OR	Adjusted OI
	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI) 0	(95% CI)	(95% CI)	(95% CI)
N = 1/C : 1	0.89	0.99	0.76	0.89	0.66	0.78	0.62	0.75	0.63		0.59	0.78
Neck/Cervical	(0.79-1.01)	(0.87-1.12)	(0.67-0.88)	(0.77-1.03)	(0.57-0.76)	(0.67-0.91)	(0.52-0.74)	(0.62-0.90)	(0.52-0.77)	(0.67-1.00)	(0.52-0.67)	(0.68-0.89
Shoulder	0.87	0.92	0.87	0.94	0.83	0.93	0.80	0.88	1.10 <u>e</u>	1.27	0.98	1.16
Shoulder	(0.75-1.00)	(0.79-1.06)	(0.74-1.02)	(0.79-1.10)	(0.71-0.99)	(0.79-1.11)	(0.66-0.98)	(0.72-1.08)	(0.90-1.34)		(0.85-1.13)	(1.00-1.34
Upper arm	0.77	0.98	0.60	0.81	0.56	0.76	0.62	0.81	0.89 3	1.23	0.73	1.01
opper unit	(0.60-1.00)	(0.76-1.27)	(0.44-0.81)	(0.60-1.11)	(0.41-0.77)	(0.54-1.05)	(0.42-0.89)	(0.55-1.19)	(0.63-1.28)	<u>`</u>	(0.56-0.94)	(0.77-1.33
Elbow	0.73	0.77	0.64	0.70	0.95	0.99	0.92	0.93	0.90 N	0.94	1.19	1.30
	(0.54-0.97)	(0.57-1.03)	(0.46-0.89)	(0.50-0.98)	(0.70-1.30)	(0.72-1.37)	(0.64-1.32)	(0.64-1.37)	(0.60-1.34) 0.74		(0.93-1.53)	(0.99-1.70
Forearm	0.91 (0.65-1.28)	1.08 (0.76-1.52)	0.53 (0.34-0.82)	0.63 (0.40-0.99)	0.72 (0.47-1.07)	0.85 (0.55-1.30)	0.80 (0.50-1.29)	0.96 (0.59-1.55)	(0.43-1.26)	0.90 (0.52-1.54)	0.98 (0.70-1.36)	1.17 (0.82-1.65
	0.86	1.07	0.57	0.74	0.63	0.81	0.79	1.00	0.71	0.95	0.86	1.15
Wrist	(0.70-1.07)	(0.86-1.34)	(0.43-0.74)	(0.57-0.98)	(0.48-0.82)	(0.62-1.07)	(0.58-1.06)	(0.74-1.37)	(0.50-0.99	(0.67-1.34)	(0.70-1.07)	(0.91-1.44
TT 1	0.68	0.81	0.44	0.57	0.47	0.59	0.60	0.74	0.60	0.77	0.57	0.74
Hand	(0.53-0.88)	(0.62 - 1.05)	(0.32-0.61)	(0.40-0.79)	(0.34-0.66)	(0.41-0.83)	(0.41-0.87)	(0.50-1.09)	(0.40-0.91	(0.50-1.18)	(0.44-0.75)	(0.56-0.99
Eineene	0.85	0.91	0.63	0.72	0.65	0.71	0.80	0.93	0.71 9	0.81	0.75	0.84
Fingers	(0.66-1.10)	(0.70 - 1.19)	(0.46-0.86)	(0.52-0.99)	(0.47-0.86)	(0.51-0.99)	(0.56-1.14)	(0.65-1.34)	(0.48-1.07	(0.53-1.22)	(0.58-0.98)	(0.64-1.11
Thoracic spine	0.75	0.77	0.83	0.90	0.71	0.78	0.69	0.74	0.54 👼	0.64	0.63	0.77
Thoracte spine	(0.63-0.90)	(0.64-0.93)	(0.69-1.02)	(0.74-1.10)	(0.58-0.88)	(0.63-0.97)	(0.54-0.89)	(0.57-0.97)	(0.40-0.73)		(0.52-0.76)	(0.63-0.93
Ribs	0.85	0.98	0.74	0.88	0.60	0.74	1.04	1.18	0.69	0.88	0.78	0.90
	(0.59-1.21)	(0.68-1.42)	(0.49-1.11)	(0.58-1.34)	(0.38-0.95)	(0.46-1.17)	(0.66-1.62)	(0.73-1.88)	(0.39-1.22		(0.54-1.11)	(0.62-1.36
Lower back	0.91 (0.80-1.03)	0.93 (0.82-1.06)	0.85 (0.73-0.97)	0.91 (0.78-1.05)	0.77 (0.67-0.90)	0.84 (0.72-0.97)	0.69 (0.57-0.82)	0.76 (0.63-0.91)	0.85 (0.71-1.03)	0.96 (0.79-1.16)	0.79 (0.70-0.90)	0.93 (0.81-1.06
	0.70	0.94	0.45	0.61	0.68	0.97	0.67	0.89	0.91	1.33	0.60	0.82
Abdomen	(0.52-0.95)	(0.69-1.28)	(0.31-0.67)	(0.41-0.91)	(0.48-0.97)	(0.68-1.40)	(0.44-1.02)	(0.57-1.37)	(0.60-1.38)		(0.44-0.83)	(0.59-1.14
	1.00	1.11	0.77	0.86	0.92	1.13	1.02	1.15	0.96	1.19	1.10	1.37
Pelvis/Gluteals	(0.78-1.28)	(0.86-1.43)	(0.57-1.03)	(0.64-1.17)	(0.69-1.23)	(0.84-1.52)	(0.74-1.41)	(0.81-1.62)	(0.67-1.39)	(0.82-1.73)	(0.86-1.40)	(1.06-1.76
II.	1.06	1.05	0.93	0.96	1.05	1.09	0.93	0.97	1.24	1.37	0.97	1.17
Hip	(0.87-1.30)	(0.85-1.29)	(0.74-1.17)	(0.76-1.21)	(0.84-1.32)	(0.87-1.38)	(0.71-1.22)	(0.73-1.29)	(0.94-1.63)	(1.03-1.81)	(0.79-1.18)	(0.95-1.45
Groin	0.94	1.04	0.72	0.80	0.98	1.05	1.08	1.20	1.31 7	1.40	1.28	1.40
UIUIII	(0.65-1.34)	(0.72-1.49)	(0.47-1.10)	(0.52-1.23)	(0.65-1.46)	(0.69-1.59)	(0.69-1.71)	(0.75-1.91)	(0.83-2.10)	(0.87-2.27)	(0.92-1.79)	(0.99-1.99
Thigh	0.99	1.13	0.87	0.99	1.24	1.41	1.39	1.59 (1.13-2.25)	1.60 NA	1.82	1.37	1.51
Tingh	(0.75-1.31)		(0.63-1.19)		(0.92-1.68)	(1.03-1.92)	(0.99-1.95)	(1.13-2.25)	(1.13-2.27)	(1.28-2.61)	(1.05-1.78)	
Knee	1.02	1.08	1.04	1.10	1.17	1.25	1.12	1.22	1.43 Q	1.55	1.16	1.30
	(0.88-1.19) 0.77	(0.92-1.25) 0.93	(0.88-1.22) 0.82	(0.93-1.30) 1.04	(0.99-1.37)	(1.06-1.50) 1.31	(0.93-1.36)	(1.01-1.49) 1.43	(1.18-1.75) 0.95	(1.27-1.90) 1.22	(1.00-1.34)	<u>(1.12-1.51</u> 1.34
Lower leg	(0.59-1.00)	(0.93)	(0.62-1.07)	(0.78-1.39)	(0.77-1.34)	(0.98-1.73)	(0.83-1.55)	(1.04-1.97)	0.95 产 (0.66-1.36)		(0.81-1.31)	(1.04-1.73
-	1.09	1.14	1.19	1.24	1.42	1.47	1.48	1.55	1.70	1.79	1.69	1.85
Ankle/Achilles	(0.87-1.36)	(0.90-1.43)	(0.93-1.52)	(0.96-1.59)	(1.12-1.81)	(1.14-1.88)	(1.12-1.94)	(1.17-2.06)	(1.28-2.26)		(1.37-2.08)	(1.49-2.31
	1.22	1.28	1.12	1.25	1.08	1.24	1.10	1.26	1.23	1.50	1.17	1.53
Foot/Toes	(0.99-1.52)	(1.02-1.60)	(0.88-1.42)	(0.98-1.61)	(0.84-1.38)	(0.96-1.60)	(0.82-1.47)	(0.93-1.71)	(0.91-1.67)		(0.94-1.45)	(1.22-1.92

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

36/bmjop Abbreviations: CI, Confidence Interval; MSK, Musculoskeletal; OR, Odds Ratio; PA, Physical Activity; WHO, World Health Brganization Footnote: A group of participants who did not meet the WHO recommendations of PA (i.e. PA less than 150 min per week) was set as the reference group. The model was adjusted for sex, age, employment status, and depression risk. -059525


Table 3. Association of PA with the Number of MSK-Pain Locations

Number of					Dos	e of WHO Gu	ideline-Base	ed PA		5		
MSK-Pain	150-3	00 min	300-4	50 min	450-6	00 min	600-7	50 min	750-9	00 min	900-	+ min
Locations	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)		Crude OR (95% CI)	Adjusted OR (95% CI)						
Minimum	1.06	1.10	1.04	1.12	1.01	1.11	0.92	1.04	1.09	1.20	1.05	1.30
1 location	(0.95-1.18)	(0.98-1.23)	(0.93-1.17)	(0.99-1.27)	(0.89-1.14)	(0.98-1.26)	(0.80-1.06)	(0.90-1.20)	(0.80-1.28)		(0.94-1.17)	(1.16-1.45)
Minimum	0.89	0.97	0.80	0.90	0.80	0.93	0.86	1.00	0.93	5 1.12	0.88	1.08
3 locations	(0.78-1.01)	(0.85-1.11)	(0.70-0.93)	(0.78-1.04)	(0.69-0.93)	(0.80-1.08)	(0.72-1.02)	(0.84-1.19)	(0.77-1.12)		(0.77-0.99)	(0.94-1.23)
Minimum	0.76	0.84	0.65	0.75	0.61	0.73	0.74	0.85	0.87	1.09	0.83	1.06
5 locations	(0.62-0.93)	(0.69-1.03)	(0.51-0.82)	(0.60-0.95)	(0.48-0.78)	(0.57-0.93)	(0.56-0.97)	(0.64-1.13)	(0.66-1.16)	(0.82-1.45)	(0.68-1.01)	(0.87-1.29)
Minimum	0.70	0.76	0.32	0.36	0.57	0.64	0.64	0.67	0.62 (0.31-1.23)	0.70	0.61	0.67
10 locations	(0.45-1.07)	(0.49-1.17)	(0.17-0.61)	(0.19-0.68)	(0.34-0.98)	(0.37-1.10)	(0.35-1.19)	(0.35-1.40)		(0.35-1.40)	(0.39-0.95)	(0.42-1.06)

Abbreviations: CI, Confidence Interval; MSK, Musculoskeletal; OR, Odds Ratio; PA, Physical Activity; WHO, World Health Örganization

Footnote: A group of participants who did not meet the WHO recommendations of PA (i.e. PA less than 150 min per week) was set as the reference group. The model was adjusted for sex, age, employment status, and depression risk.

//bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright.



Galley-proof base (ASAP) 14.03.2022, 12:20 Page 23 of 34

https://survey.studiumdigitale.uni-frankfurt.de/admin/preview.php?t=4o7... BMJ Open

		Pag
Please indicate your se	ex.	SD01
O Male		
○ Female		
O Non-binary		
O I prefer not to say		
What is your age?		SD02
years		
Where do you live?		(SD04
[Please choose]	▼	
Where do you work sir	nce the virus outbreak in your country?	(SD03
Remotely (Home of	ffice)	
Office/regular place	e of work	
O both		
O I do not have a form	nal employment.	
I do not want to tell.		
		Pag
		ray
Do you currently work	part-time or full-time?	SD05
O full-time		
O part-time		
O I do not want to tell		

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright.

	Раде 0- к
Have you had any symptoms beyond a minor respiratory tract infection since the vi	rus outbreak in your ^{(KH01 ©}
country? Only choose yes, if you had to stay in bed or reduce your regular movement behavi	-
O yes	
O no	
	Dava 0
	Page 0 Coror
Have you been diagnosed with the novel Coronavirus?	(КН02 🗉
Only choose "yes" if you have been diagnosed by a helathcare professional.	
⊖ yes	
O no	
◯ I do not want to tell	
	Page 0
	Einschraenkur
move freely due to restrictions of public life (e.g. prohibition of face-to-face contact,	
move freely due to restrictions of public life (e.g. prohibition of face-to-face contact, lockdowns).	ty to leave your home and
move freely due to restrictions of public life (e.g. prohibition of face-to-face contact,	ty to leave your home and
move freely due to restrictions of public life (e.g. prohibition of face-to-face contact, lockdowns).	ty to leave your home and
move freely due to restrictions of public life (e.g. prohibition of face-to-face contact, lockdowns).	ty to leave your hom e and business closures,
Please indicate the approximate number of days you have been limited in your abilit move freely due to restrictions of public life (e.g. prohibition of face-to-face contact, lockdowns). days From here, we will repeatedly ask how certain situations and conditions have changed in y of the novel coronavirus. For instance, if you just stated to be restricted in your ability to m please always compare the situation during these last 14 days to 14 typical days prior to th days, please compare these 30 days with 30 typical days prior to the outbreak.	ty to leave your hom e and business closures, Page 0 Erklaerun vour country since the outpreat ove freely since 14 days,
move freely due to restrictions of public life (e.g. prohibition of face-to-face contact, lockdowns).	ty to leave your hom e and business closures, Page 0 Erklaerur vour country since the outprean ove freely since 14 days,
From here, we will repeatedly ask how certain situations and conditions have changed in y of the novel coronavirus. For instance, if you just stated to be restricted in your ability to m please always compare the situation during these last 14 days to 14 typical days prior to the	ty to leave your home and business closures, Page (Erklaeru vour country since the outbread ove freely since 14 days, ne outbreak. If you chose 30

Page 08

	KAFrei
	EXA09 how physically active you have been in your free time (including commuting from and to work). erate and vigorous activities – light activities do not need to be reported.
	those where your hearbeat increases and you breathe faster (e.g. brisk walking, cycling as a sa exercise, heavy gardening, running or recreational sports).
	nose that get your heart racing, make you sweat and so short of breath that you find it difficult to unning, cycling at high speeds, cardio training, weigh-lifting or team sports such as football).
Ioderate and vigorous	KA01 •
-	
• •	much time do you spend in total on both moderate and vigorous physical activities? with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more than
before the outbreak	Minutes per week.
since the outbreak	Minutes per week.
10 minutes.	
before the outbreak	Minutes per week.
since the outbreak	Minutes per week.

				Раде ка
Physical activity in yo	ur iob			KA10
While the previous que	stions addressed free t	ime, the following two foc activities do not need to be		time. Again, we only a
Moderate activities are	those where your hearl	beat increases and you br	eathe faster (e.g. brisk wa	alking).
<u>Vigorous</u> activities are t speak (e.g. repeated lift		art racing, make you swea	t and so short of breath t	hat you find it difficul
Moderate and vigorou	is activities			KA07 E
On a typical week, how	much time do you spe	nd in total on both modera	te and vigorous physical	activities?
Please sum all activities 10 minutes.	s with a minimal duratio	n of 10 minutes. Enter 0, i	if there was not at least or	ne activity of m
before the outbreak	Minutes	per week.		
since the outbreak	Minutes	per week.		
before the outbreak	Minutes pe			
since the outbreak	Minutes pe	er week.		
				Daga
				•
		is in public life on your c bing, walking, etc.)	overall level of activity (i	Aktivitaetsniv
Please indicate the im light and very light act strongly negative influence			overall level of activity (r modest positive impact	Page Aktivitaetsniv now including also strongly positive influence
light and very light act strongly negative	tivities such as shopp slight negative	bing, walking, etc.)	modest positive	Aktivitaetsniv
light and very light act strongly negative	tivities such as shopp slight negative	bing, walking, etc.)	modest positive	Aktivitaetsniv

	Раде 11 каз
How did you engage in sport or exercise before the virus outbreak in your country?	(KA05 🗈
Multiple choice possible.	
Gym	
Sports club	
Self-organised outdoor (e.g. running, cycling in nature)	
Self-organised at home (e.g. cycle ergometer, dumbbells)	
others	
not at all	
How did you engage in sport or exercise since the virus outbreak in your country?	(KA06 🗉
Multiple choice possible.	
self-organised outdoor (e.g. running, cycling in nature)	
self-organised at home (e.g. cycle ergometer, dumbbells)	
others	
not at all	
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

						Page 12 Pain
Please indicate whether you suffered	l from musculoskeletal pain	<u>before</u> an	d/or <u>sinc</u>	<u>e</u> the virus	outbreal	(WB13 🗉
The musculoskeletal system comprises and their functions.	all parts of the skeletal syster	n with bon	es, muscle	es, ligament	s, tendon	s, joints
	no pain	very light pain	light pain	moderate pain	strong pain	very strong pain
pefore outbreak	0	0	0	0	0	0
ince outbreak	0	0	0	0	0	0
low much did pain interfere with yοι	ur normal work (including bo	oth work c	outside th	e home and	d housev	
,	no pain	not at all		moderately	quite a bit	extremely
					Dit	extremely
before outbreak	0	0	0	0	0	0
For peer review	only - http://bmjopen.bmj.com	n/site/abou	t/guidelin	es.xhtml		

https://survey.studiumdigitale.uni-frankfurt.de/admin/preview.php?t=4o7... BMJ Open

			Page Check
question('WB15', 'co			(
Please list all body	regions where you had pain <u>before</u> (left boxes) a	and/or <u>side</u> (right boxes) the or	nset WB15
		before	since
Multiple selection	s in both columns are possible.	outbreak	outbrea
l did not have pain.			
Neck/cervical spine	3		
Shoulder			
Upper arm			
Elbow			
Forearm			
Wrist			
Hand			
Fingers			
Thoracic spine/upp	er back		
Sternum/Ribs			
Lumbar spine/lowe	r back		
Abdomen			
Pelvis/buttock			
Hip			
Groin			
Thigh			
Knee			
Lower leg			
Ankle/achilles tende	on		
Foot/toes			

WHO5

Please indicate for each of the five statements which	is closest t	o how you	ı have bee	en feeling <u> </u>	<u>before</u> the	WB10 outprea
of the novel coronavirus.			a little			
	all the time	most of the time	more than half of the time	a little less than half of the time	every now and then	at no tim
Before the outbreak						
I have felt cheerful and in good spirits	0	0	0	0	0	0
I have felt calm and relaxed	0	0	0	0	0	0
I have felt active and vigorous	0	0	0	0	0	0
I woke up feeling fresh and rested	0	0	0	0	0	0
my daily life has been filled with things that interest me	0	0	0	0	0	0
Please indicate for each of the five statements which	is ciosest t	o how you	i have bee	en teeling s	since the	outprea
	all the time	o how you most of the time	a little more than half of the time	a little less than half of the time	every now and then	
	all the	most of	a little more than half of the	a little less than half of the	every now and	
of the novel coronavirus.	all the	most of	a little more than half of the	a little less than half of the	every now and	at no tir
of the novel coronavirus. Since the outbreak	all the	most of	a little more than half of the time	a little less than half of the time	every now and then	at no tir
of the novel coronavirus. Since the outbreak I have felt cheerful in good spirits	all the	most of the time	a little more than half of the time	a little less than half of the time	every now and then	at no tii
of the novel coronavirus. Since the outbreak I have felt cheerful in good spirits I have felt calm and relaxed	all the	most of the time	a little more than half of the time	a little less than half of the time	every now and then	at no tii
I have felt cheerful in good spirits I have felt calm and relaxed I have felt active and vigorous	all the	most of the time	a little more than half of the time	a little less than half of the time	every now and then	at no ti
of the novel coronavirus. Since the outbreak I have felt cheerful in good spirits I have felt calm and relaxed I have felt active and vigorous I woke up feeling fresh and rested my daily life has been filled with things that	all the	most of the time	a little more than half of the time	a little less than half of the time	every now and then	at no ti

										Page 1 v
			e the influenc gyms, bans							
psychologic	cal well-b	eing								
strong negative influence	0	0	0	0	no influence	0	0	0	0	stron positiv influen
physical we	ll-being									WB20
strong negative influence				_	no influence		_			stron positiv influen
0	0	0	0	0	0	0	0	0	0	0
Since the or situation.	utbreak o	f the nove	el coronaviru	s, sport	and/or phys	ical activ	ity helps m	e deal with	n the ove	WB12 rah
completely disagree		0	rather disagree	0	0		rather agree	0	0	totall agree
0	0	0	0	0	0	0	0	0	0	0
										Page
										0
Would you l	be interes	sted in a fi	ree online ex	ercise ti	raining prog	ram that y	you could u	se home-l	oased de	TP01 spite the
restrictions	in public	life?								
O yes										
O no										

	Page 17 TP2
How much time per week would you like to spend for such a training program?	(TP02 •
Minutes per training session/workout	
How often would you like to exercise?	TP04 •
O daily	
O 4-6 times a week	
O 3-4 times a week	
O 1-2 times a week	
Which type of exercise would you like to perform?	(TP03 🗉
Multiple choice possible.	
Strength	
Coordination/Balance	
Flexibility/Stretching	
Relaxation	
no preference	
	Page 18
	EN04
Thank you for participating!	EN05
You are welcome to visit us on our homepage as well as on Facebook and Instagram:	ENUS
Usersen and Esselvation in the man	
Homepage Facebook Instagram	
Please feel free to share this survey with your family, work colleagues and friends! Thank you!	

Last Page

Thank you for participating!

Your answers have been saved, you can now close the browser window.

Imprint ASAP – 2020

		BMJ Open	Page
	STR	OBE 2007 (v4) Statement—Checklist of items that should be included in reports of <i>cross-sectional studies</i>	
Section/Topic	ltem #	Recommendation 6	Reported on page #
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used term in the title or the abstract	1-3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was	1-3
Introduction	1		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	3-4
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5
Participants	6	(<i>a</i>) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Gige diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-6
Bias	9	Describe any efforts to address potential sources of bias	5-6
Study size	10	Explain how the study size was arrived at	5-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groven and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5-6
		(a) Describe an statistical methods, including those used to control for control nor contro nor control nor control nor control nor control nor control nor c	5-6
		(c) Explain how missing data were addressed	5-6
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
Results		co pyright.	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

34		BMJ Open	
			1
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility,	6
		confirmed eligible, included in the study, completing follow-up, and analysed B (b) Give reasons for non-participation at each stage B	
			N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on ఉorea potential confounders	6
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	7
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence	7-8
		interval). Make clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	7-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful ting period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses $\stackrel{\Theta}{\exists}$	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	8-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-12
Other information		April	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in centrol studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine 🕏 rg/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.s α obe-statement.org.

by copyright.

Association between physical activity and musculoskeletal pain: an analysis of international data from the ASAP survey

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-059525.R2
Article Type:	Original research
Date Submitted by the Author:	15-Aug-2022
Complete List of Authors:	Rhim, Hye Chang; Harvard Medical School, Department of Physical Medicine and Rehabilitation; Spaulding Rehabilitation Hospital Tenforde, Adam; Harvard Medical School, Department of Physical Medicine and Rehabilitation; Spaulding Rehabilitation Hospital Mohr, Lisa; Goethe University Frankfurt, Department of Sports Medicine Hollander, Karsten; MSH Medical School Hamburg, Institute of Interdisciplinary Exercise Science and Sports Medicine Vogt, Lutz; Goethe-Universitat Frankfurt am Main, Department of Sports Medicine Groneberg, David; Goethe University Frankfurt, Institute of Occupational Medicine, Social Medicine and Environmental Medicine Wilke, Jan; Goethe-Universitat Frankfurt am Main, Institut of Occupational Medicine, Social Medicine and Environmental Medicine; University of Klagenfurt, Department of Movement Sciences
Primary Subject Heading :	Sports and exercise medicine
Secondary Subject Heading:	Epidemiology, Public health, Sports and exercise medicine, Rehabilitation medicine, Rheumatology
Keywords:	SPORTS MEDICINE, REHABILITATION MEDICINE, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY, PAIN MANAGEMENT





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

relievont

Association between physical activity and musculoskeletal pain: an

analysis of international data from the ASAP survey

Hye Chang Rhim*, Adam Tenforde*, Lisa Mohr, Karsten Hollander, Lutz Vogt, David A.

Groneberg, Jan Wilke⁺

* The first two authors equally contributed to this work

Hye Chang Rhim, Department of Physical Medicine and Rehabilitation, Harvard Medical School/Spaulding Rehabilitation Hospital, Boston, MA, USA

Adam Tenforde, Department of Physical Medicine and Rehabilitation, Harvard Medical School/Spaulding Rehabilitation Hospital, Boston, MA, USA

Lisa Mohr, Department of Sports Medicine, Goethe University Frankfurt, Frankfurt, Germany

Karsten Hollander, Institute of Interdisciplinary Exercise Science and Sports Medicine, Medical School Hamburg, Hamburg, Germany

Lutz Vogt, Department of Sports Medicine, Goethe University Frankfurt, Frankfurt, Germany

David A. Groneberg, Institute of Occupational, Social, and Environmental Medicine, Goethe University, Frankfurt, Germany

Jan Wilke, Institute of Occupational, Social, and Environmental Medicine, Goethe University, Frankfurt, Germany / Department of Movement Sciences, University of Klagenfurt, Austria

[‡] Corresponding author: Jan Wilke, Institute of Occupational, Social, and Environmental Medicine, Goethe University, , Frankfurt, Germany, Email: jan.wilke@aau.at

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

BMJ Open

ABSTRACT

Objective: To explore the association of physical activity (PA) with musculoskeletal pain (MSK-pain).

Design: Cross-sectional study

Setting: 14 countries (Argentina, Australia, Austria, Brazil, Chile, France, Germany, Italy, the Netherlands, Singapore, South Africa, Spain, Switzerland, and the United States of America)

Participants: Individuals aged 18 or older

Primary and secondary outcome measures: PA volumes were assessed with an adapted version of the Nordic Physical Activity Questionnaire-short (NPAQ-short). Prevalence of MSK-pain was captured by means of a 20-item checklist of body locations. Based on the WHO recommendation on PA, participants were classified as non-compliers (0-150 min/week), compliers (150-300 min/week), double compliers (300-450 min/week), triple compliers (450-600 min/week), quadruple compliers (600-750 min/week), quintuple compliers (750-900 min/week), and top compliers (more than 900 min/week). Multivariate logistic regression was used to obtain adjusted odds ratios of the association between PA and MSK-pain for each body location, correcting for age, sex, employment status, and depression risk.

Results: A total of 13,741 participants completed the survey. Compared to non-compliers, compliers had smaller odds of MSK-pain in one location (thoracic pain, OR 0.77, CI 0.64-0.93). Double compliance was associated with reduced pain occurrence in six locations (elbow, OR 0.70, CI 0.50-0.98; forearm, OR 0.63, CI 0.40-0.99; wrist, OR 0.74, CI 0.57-0.98; hand, OR 0.57, CI 0.40-0.79; fingers, OR 0.72, 0.52-0.99; abdomen, OR 0.61, 0.41-0.91). Triple to top compliance was also linked with lower odds of MSK-pain (five locations in triple compliance, three in quadruple compliance, two in quintuple compliance, three in top compliance), but, at the same time, presented increased odds of MSK-pain in some of the other locations.

Conclusion: A dose of 300-450 min WHO-equivalent PA/week was associated with lower odds of MSK-pain in six body locations. On the other hand, excessive doses of PA were associated with higher odds of pain in certain body locations.

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

Strengths and Limitations of this study

- This is the first large-scale analysis of associations between MSK pain and PA considering multiple anatomical locations
- Large sample size enabled to investigate the associations between different degrees of compliance to physical activity recommended by WHO and MSK-pain
- Administration of the survey in 14 countries allowed participation of diverse populations

to beet eview only

- Self-reported data may be subject to recall bias
- Cross-sectional observational design prohibits causal inference

INTRODUCTION

Musculoskeletal pain (MSK-pain) is a common condition that can have negative physical, psychological, and social impacts.[1] A summary of previous epidemiological studies conducted with diverse techniques and populations revealed that MSK-pain affects between 13.5% and 47% of the general population, with prevalence higher in women and increasing strongly with age.[2] Musculoskeletal conditions contribute to disability, especially in older age groups.[2] It has been reported that disability-adjusted life-years (DALYs), which reflects the years of life lost due to premature mortality and years of life lived with disability, increased by 62% between 1990 and 2016 around the world with 20% surge during the ten-year interval from 2006 to 2016.[3] Most of the increased burden has derived from disability due to increased aging population affected by MSK conditions, , and the burden of MSK disorders is expected to increase even more in the future.[4]

Achieving sufficient physical activity (PA) is associated with a variety of positive health outcomes such as substantial risk reduction in all-cause mortality[5] as well as multiple chronic diseases including type 2 diabetes and metabolic syndrome,[6] cancer,[6] and cardiovascular disease.[7] In the light of these positive impacts, World Health Organization (WHO) recommends 150-300 min of moderate-intensity PA, or 75-150 min of vigorous-intensity PA, or aerobic PA with some combination of moderate and vigorous intensities.[8] PA is also considered one of the most important strategies to prevent and manage MSK-pain.[9] However, compared to the available evidence on the association of PA with non-communicable disease, there seems to be a fewer number of studies on the topic of PA and MSK-pain. . Furthermore, it is still less clear whether the amounts recommended by WHO are sufficient to elicit benefits in terms of addressing MSK-pain. The few available studies examining the relation of regular PA

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

and MSK-pain tended to focus on influence of PA for specific body locations or specific diagnoses such as low back pain, neck pain, or osteoarthritis and found inconsistent results.[10] Other studies have evaluated the associations between PA and pain in occupational settings such as among physical therapists or teaching staff.[11,12] Particularly, the interplay between the volume of PA and MSK-pain within the general population has been less explored.

The purpose of this study was to explore the association of total PA with presence of MSK-pain in a variety of anatomical locations including both upper and lower extremities. We hypothesized that greater time spent in PA than WHO recommendation would be associated with the absence of MSK-pain in more body regions, but that excess time performing PA might be associated with the presence of MSK-pain in more body regions.

METHODS

Study Design

This article presents an explorative analysis of pre-pandemic baseline data on PA and MSK-pain assessed during the ASAP (Activity and Health during the SARS-CoV-2 Pandemic) survey. The survey was administered with results collected between April 3 and May 9, 2020, including participants from 14 countries (Argentina, Australia, Austria, Brazil, Chile, France, Germany, Italy, the Netherlands, Singapore, South Africa, Spain, Switzerland, and the United States of America (USA)).[13-16] Ethical approval was obtained from the ethics committees of the study center and collaborating institutions. All participants provided digital informed consent.

Participants

Eligibility for participation in the ASAP survey was limited to individuals aged 18 or older living in participating countries. Recruitment was performed online using promotion by health-related organizations, mailing lists, and social media advertising (e.g. Facebook, Instagram, Twitter).

Questionnaire

To capture PA, the ASAP survey incorporated an adapted version of the Nordic Physical Activity Questionnaire-short (NPAQ-short). The instrument retrospectively assessed the amounts of moderate and combined moderate and vigorous activities (min/week) during leisure and occupational time. Moderate activities were defined as those that increase heart rate or breathing, and vigorous activities were defined as those that make heart racing, sweating, and shortness of breath. The questionnaire asked how much time participants spent in total on both moderate and vigorous PA on a typical week, and the time spent in all activities with a minimal duration of 10 minutes was asked to be added and entered in the form. The NPAQ-short has been shown to be reliable (test-retest reliability: rho = 0.80 to 0.82) and valid for observing compliance with the WHO recommendations on PA.[17] The questionnaire was available in 7 different languages (Dutch, English, German, French, Italian, Brazilian-Portuguese, Spanish), and clarity and comprehensibility were validated by native speakers through forward and backward translation.

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

Prevalence of MSK-pain was captured by means of binary responses (yes/no) to an adapted 20-item checklist from a consensus statement on epidemiological injury reporting.[18] Body locations were categorized as follows: neck/cervical spine, shoulder, upper arm, elbow,

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

forearm, wrist, hand, fingers, thoracic spine, ribs, lower back, abdomen, pelvis/gluteal, hip, groin, thigh, knee, lower leg, ankle/Achilles tendon, foot/toe.

The English version of the ASAP survey can be found in Supplemental File 1.

Data Processing and Statistical Analysis

Self-reported PA was categorized as multiples of compliance with WHO guidelines which recommend 150-300 minutes/week of moderate activity, 75-150 minutes/week of vigorous activity, or any adequate combination of both.[8] We used the formula (minutes of moderate-to-vigorous PA – minutes of vigorous PA) + minutes of vigorous PA *2 to classify participants as non-compliers (0-150 min/week), compliers (150-300 min/week), double compliers (300-450 min/week), triple compliers (450-600 min/week), quadruple compliers (600-750 min/week), quintuple compliers (750-900 min/week), and top compliers (more than 900 min/week). In addition to the assessment of PA, participants were asked where they worked in multiple choices which also included a 'no employment' option, and the answers to this question were used to categorize participants into being employed or not employed for our analysis. Also, the WHO-Well-Being Index (WHO-5) was used to capture depression risk as validated by previous research.[19]

For each body region, univariate binary logistic regression was conducted to calculate the unadjusted odds ratio (OR) of the association between pain (dependent variable: yes/no) and PA. In a similar way, univariate binary logistic regression was then used to identify associations of pain (dependent variable) and potential confounding variables (sex, age, employment status, depression risk). Finally, multivariate binary logistic regression was performed including these confounding variables (if relevant) to obtain the adjusted ORs and 95% confidence interval (CI)

of the association between the volume of PA and pain (dependent variable). As participants may have a strongly varying number of pain locations and as the impact of pain on the individual may vary with the number of affected body regions, additional analyses, using the same procedures as described above (binary logistic regression corrected for confounders), were performed to obtain adjusted OR for pain in only one, at least 3, 5, or 10 body locations.

All data analyses were conducted using SPSS 22 (SPSS INC., Armonk, NY, USA), and the significance level was set to $\alpha = 0.05$.

Patient and Public Involvement

Members of the target population without medical background were involved in the designing phase of the ASAP questionnaire. The questionnaire was face validated for each language with five non-academic individuals. Feedback on comprehension and clarity of the wording was used.

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

RESULTS

Valid datasets were identified for 13,741 participants (38 ± 15 years, minimum 18 and maximum 100, 59% females). The demographic data are summarized in the Table 1. 2604 individuals did not meet the WHO recommendation of PA while n=2735 belonged to 150-300 min group, n=1957 to 300-450 min group, n=1749 to 450-600 min group, n=1066 to 600-750 min group, n=849 to 750-900 min group, and n=2781 to 900+ min group. Comprehensive results are summarized in the Table 2 and 3.

Compared to inactive individuals, simple guideline compliance was associated with lower odds of suffering from MSK-pain in one body location (thoracic pain, OR 0.77, CI 0.64-

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

0.93 Table 1). Double compliance was associated with lower odds of suffering from MSK-pain in six locations (elbow, OR 0.70, CI 0.50-0.98; forearm, OR 0.63, CI 0.40-0.99; wrist, OR 0.74, CI 0.7-0.98; hand, OR 0.57, CI 0.40-0.79; fingers, OR 0.72, CI 0.52-0.99; abdomen, OR 0.61, CI 0.41-0.91). Although higher amounts of PA were associated with lower odds of suffering from MSK-pain in variable numbers of locations (five body locations in triple compliance, three in quadruple compliance, two in quintuple compliance, three in top compliance), they were also associated with higher odds of suffering from MSK-pain in other locations. Specifically, triple compliance was associated with presence of MSK-pain in thigh (OR 1.41, CI 1.03-1.92), knee (OR 1.25, CI 1.06-1.50), and ankle/Achilles tendon (OR 1.47, CI 1.14-1.88). Quadruple compliance increased pain locations to four, quintuple compliance to six, and top compliance to seven.

Triple compliance was associated with lower odds to have a total of 5 or more (OR 0.75, CI 0.60-0.95) or 10 or more (OR 0.36, CI 0.19-0.68) pain locations, and quadruple compliance was associated with lower odds to have 5 or more pain locations (OR 0.73, CI 0.57-0.93). However, quintuple and top compliances were associated with higher odds of having a minimum one pain location (OR 1.28, CI 1.10-1.51 and 1.30, CI 1.16-1.45 respectively).

DISCUSSION

The purpose of the present study was to explore the relation between PA and MSK-pain. Previous research focused on the impact of PA on specific locations of MSK-pain (e.g., low back and neck[20]) or certain occupational settings.[11,12] Our large-scale multinational study is novel in that it identified the associations between different degrees of compliance to PA recommended by WHO and multiple body locations in the general population after adjusting for multiple

BMJ Open

cofounding factors including age, which is known to be positively associated with MSK-pain prevalence.

Guideline compliance (150-300 min per week) was weakly associated with MSK pain, showing lower odds of having pain only in thoracic spine but higher odds in foot/toes. In contrast, double compliance (300-450 min per week) substantially increased the number of locations that were associated with lowers odds of MSK-pain to six and thus seems to represent the optimal dose when PA is undertaken to prevent MSK. Finally, higher levels of PA (triple to top compliance) were associated with less odds of having pain in multiple upper body locations but paradoxically contributed to higher odds of having lower extremity pain. Notably, participating in 300-600 min of PA per week was associated with lower spine. In contrast, participating in greater than 450 min of PA per week was associated with higher odds of having pain in the lower extremity.

Time spent in PA and pain in neck, back, and upper extremity

A previous systematic review showed that there was limited evidence for no association between PA and neck pain.[20] However, our study found that participating in PA between 450-900+ min was associated with lower odds of having pain in neck/cervical spine. Several epidemiological studies have demonstrated that certain postures sustained for prolonged duration combined with sedentary lifestyle were associated with neck pain.[21-23] Therefore, increased PA levels may be helpful to consider in those at risk for neck pain. BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

Association between PA and thoracic spine has been less explored,[24] but a recent observational study found that PA less than 150 min per week was associated with reduced

thoracic mobility.[25] Our findings build on previous research in that PA less than 150 min per week is also associated with higher odds of having pain in the thoracic spine.

While it is generally accepted that PA and exercise are beneficial in the management of acute and chronic low back pain, a previous systematic review could not identify either positive or negative relationship.[26] One study suggested that the relationship between the level of activity and back pain might be explained by a U-shaped curve that suggests both low and excessive PA may increase the risk of low back pain.[27] Our findings partly support this concept as PA of 450-750 min was associated with lower odds of low back pain while lower or higher PA than that range did not have significant association.

PA in the range of 300-600 min was also associated with lower odds of having pain in several locations in the upper extremity such as elbow, forearm, wrist, hand, and fingers. PA exceeding 750 min was associated with higher odds of shoulder pain. The underlying mechanisms of how PA modulates pain are not completely understood, but several pathways have been proposed. Animal study findings suggest regular PA may act on the central nervous system (CNS) and alter rate of pain hypersensitivity, dysregulation of pain modulation, and development of chronic pain.[28-30] In humans, it has been proposed that PA may intervene excitability and inhibition in the CNS,[31-33] and anti-inflammatory and antioxidant effects of regular PA might diminish the processes contributing to central sensitization.[34-36] Other proposed mechanisms in humans include the activation of opioid and serotonin pathways[37] or involvement of endocannabinoid system[38] induced from regular PA which could exert analgesic effects. While further research is needed to elucidate how much and what type of PA can induce such changes to modulate pain, our results suggest that PA between 300-600 mins per

BMJ Open

Association of PA and lower extremity pain

The association of PA to lower extremity pain was different than what was observed for upper extremity and spine conditions. Our results suggest PA exceeding 450 min was associated with higher odds of MSK-pain in lower extremity. These findings may be partially explained by higher amounts of PA are likely to involve greater use of the lower extremity. In the United States, it has been reported that walking is the most popular form of exercise followed by biking, yard work, strength training, dancing, and running, which are activities that commonly place physical demands through the lower extremity.[39] Running is one of the most popular exercises in the world and has been shown to result in lower extremity pain in multiple anatomical locations with nearly all (94.7% of runners) reporting experience of pain at least once after running.[40]

We also observed that greater PA was associated with a higher number of sites of MSKpain in the lower extremity. A dose response was observed: 450-600 min was associated with pain in three anatomical regions, 600-750 min with pain in four anatomical regions, 750-900 min with five anatomical regions, and 900+ min with six anatomical regions. The optimal PA level to reduce pain in those with existing musculoskeletal lower extremity pain is unknown. A prior study reported that a minimum of 45 total moderate-vigorous min per week was sufficient to elicit improved or sustained high function with lower-extremity symptoms regardless of age, gender, body mass index, or presence of knee osteoarthritis.[41] Our findings of PA ranging from

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

BMJ Open

150-450 min not increasing the odds of having pain in the lower extremities suggest this range might be appropriate to be safe and promote other health benefits.

Clinical implication

While the WHO 2020 guidelines on PA recommend 150-300 min of moderate-intensity PA, or 75-150 min of vigorous-intensity PA, or some equivalent combination of moderateintensity and vigorous-intensity aerobic PA per week for optimal health outcomes,[8] the current study suggests that more PA beyond the WHO recommendation may be necessary to decrease the odds of having pain particularly in the upper extremity. Our findings suggest a target of 300-450 min of PA per week could be optimal for preventing pain in the upper extremity without clear associated higher rate of lower extremity pain. Also, this range was associated with lower odds of having pain in multiple number of locations. Recognizing concerns on higher prevalence of pain in low back, neck, and thoracic spine increased during the COVID-19 pandemic,[15] PA target of the higher target of 450 min of weekly exercise may be helpful in this population. Our results suggest exceeding 450 min of PA may not be advisable for those with increased concern for lower extremity pain. Furthermore, PA above 750 minutes was associated with having at least one pain location.

Limitation

While our findings derived from a large-scale multinational study of participants, we do note potential limitations. Self-report of PA and MSK-pain are limited by reporting bias and inaccuracy including risk for over-reporting level of PA.[42,43] The cross-sectional study design limits our understanding between PA and the etiology of MSK-pain. Also, we are limited in

ability in discriminating the types of PA to report of MSK-pain by anatomical locations. We were not able to distinguish or identify bilateral MSK-pain from our questionnaire as well. Furthermore, because a separate analysis was run for each body region, there is a risk of multiple testing problem. Since our analysis was explorative in nature, further prospective cohort or interventional studies are needed to elucidate the best form and dose of PA to address MSK-pain by anatomical location and specific musculoskeletal injury, and additionally investigate the role of MSK-pain intensity instead of using a binary (yes/no) classification.

CONCLUSION

Our findings showed that PA time above the WHO recommendations was associated with

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright

lower odds of having pain in multiple locations such as neck, thoracic spine, low back, and in the

upper extremities. Especially, undertaking PA for 300-450 min per week was associated with

reduced pain occurrence in six locations, elbow, forearm, wrist, hand, fingers, and abdomen.

Acknowledgment: The authors acknowledge the valuable help from the following authors with promoting ASAP survey for data collection (in alphabetical order): Benedict Tan, Bernhard Novak, Celso Ramiréz, Chiara Fossati, Christoph Heidt, Daniel E. Lieberman, David Jimenez-Pavon, Evert Verhagen, Fabio Pigozzi, Falk Richter, Fernando Laíño, Johannes Jaunig, Julian David Pillay, Luiz Carlos Hespanhol Junior, Marcela González-Gross, Matteo Sattler, Mireille van Poppel, Pascal Edouard, Steffen Willwacher

Funding: This research received no external funding.

Data Availability Statement: Data are available upon reasonable request

Ethics Statements

-Ethics approval: This study was approved by the University of Queensland Health and Behavioural Sciences (2020000693), Ethical committee of the University of Graz (GZ. 39/62/63 ex 2019/20), Research Ethics Committee of Fundación Instituto Superior de Ciencias de la Salud (DEPINV CODE: 11/20), Research Ethics Committee of the Universidade Cidade de São Paulo (CAAE: 30555320.0.0000.0008). Institutional Ethics Committee of the University of Santiago de Chile (nº 123/2020), Saint-Etienne University Hospital Ethical Committee (IORG0007394; IRBN492020/CHUSTE), Ethics Committee of the Faculty of Psychology and Sports Sciences of Goethe University Frankfurt (no. 2020-13), Comitato di Ateneo per la Ricerca, Università degli

Studi di Roma "Foro Italico" (CAR 43/2020), Medical Ethical Committee of Amsterdam UMC (2020.192), Institutional Research Ethics Committee of Durban University of Technology (IREC 042/20), SingHealth Centralised Institutional Review Board (2020/2287), Cantonal Ethics Committee Northwest Switzerland (2020-01058), Ethics Committee of Universidad Politécnica de Madrid (20200507-1), and Partners Human Research Committee (2020P000963)

-Digital informed consent was obtained from all subjects involved in the study.

Authors Contribution: HCR/AT: data collection, interpretation, drafting and critical revision of the manuscript, LM, KH, LV, DG: data collection, critical revision of the manuscript, JW: conception/design, data collection, interpretation, critical revision of the manuscript a . None declared.

Competing interests: None declared.

1		
2 3		
4		REFERENCES
5		
6 7	1.	Paananen, M.; Taimela, S.; Auvinen, J.; Tammelin, T.; Zitting, P.; Karppinen, J. Impact of self-
8		reported musculoskeletal pain on health-related quality of life among young adults. Pain Med
9	2	2011 , <i>12</i> , 9-17.
10	2.	Cimmino, M.A.; Ferrone, C.; Cutolo, M. Epidemiology of chronic musculoskeletal pain. <i>Best Pract</i> <i>Res Clin Rheumatol</i> 2011 , <i>25</i> , 173-183.
11 12	3.	Collaborators, G.D.a.H. Global, regional, and national disability-adjusted life-years (DALYs) for
13	5.	333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories,
14		1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> 2017 , <i>390</i> ,
15		1260-1344, doi:10.1016/s0140-6736(17)32130-x.
16 17	4.	Smith, E.; Hoy, D.G.; Cross, M.; Vos, T.; Naghavi, M.; Buchbinder, R.; Woolf, A.D.; March, L. The
18		global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease
19	_	2010 study. Ann Rheum Dis 2014, 73, 1462-1469, doi:10.1136/annrheumdis-2013-204680.
20	5.	Ekelund, U.; Tarp, J.; Steene-Johannessen, J.; Hansen, B.H.; Jefferis, B.; Fagerland, M.W.;
21 22		Whincup, P.; Diaz, K.M.; Hooker, S.P.; Chernofsky, A. Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic
22		review and harmonised meta-analysis. <i>BMJ</i> 2019 , <i>366</i> .
24	6.	Lee, IM.; Shiroma, E.J.; Lobelo, F.; Puska, P.; Blair, S.N.; Katzmarzyk, P.T.; Group, L.P.A.S.W.
25	-	Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of
26 27		burden of disease and life expectancy. Lancet 2012, 380, 219-229.
27	7.	Kyu, H.H.; Bachman, V.F.; Alexander, L.T.; Mumford, J.E.; Afshin, A.; Estep, K.; Veerman, J.L.;
29		Delwiche, K.; lannarone, M.L.; Moyer, M.L. Physical activity and risk of breast cancer, colon
30		cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and
31 32	0	dose-response meta-analysis for the Global Burden of Disease Study 2013. <i>BMJ</i> 2016 , <i>354</i> .
33	8.	Bull, F.C.; Al-Ansari, S.S.; Biddle, S.; Borodulin, K.; Buman, M.P.; Cardon, G.; Carty, C.; Chaput, J P.; Chastin, S.; Chou, R. World Health Organization 2020 guidelines on physical activity and
34		sedentary behaviour. Br J Sports Med 2020 , 54, 1451-1462.
35	9.	Lin, I.; Wiles, L.; Waller, R.; Caneiro, J.P.; Nagree, Y.; Straker, L.; Maher, C.G.; O'Sullivan, P.P.B.
36 37		Patient-centred care: the cornerstone for high-value musculoskeletal pain management. Br J
38		Sports Med 2020 , 54, 1240-1242, doi:10.1136/bjsports-2019-101918.
39	10.	Geneen, L.J.; Moore, R.A.; Clarke, C.; Martin, D.; Colvin, L.A.; Smith, B.H. Physical activity and
40		exercise for chronic pain in adults: an overview of Cochrane Reviews. <i>Cochrane Database Syst</i>
41 42	11	Rev 2017.
43	11.	Ezzatvar, Y.; Calatayud, J.; Andersen, L.; Casaña, J. Are moderate and vigorous leisure-time physical activity associated with musculoskeletal pain? a cross-sectional study among 981
44		physical activity associated with musculoskeletal pains a closs-sectional study among 561 physical therapists. Am J Health Promot 2020 , 34, 67-70.
45	12.	Tami, A.M.; Bika Lele, E.C.; Mekoulou Ndongo, J.; Ayina Ayina, C.N.; Guessogo, W.R.; Lobe Tanga,
46 47		MY.; Owona Manga, L.J.; Temfemo, A.; Bongue, B.; Mandengue, S.H. Epidemiology of
48		Musculoskeletal Disorders among the Teaching Staff of the University of Douala, Cameroon:
49		Association with Physical Activity Practice. Int J Environ Res Public Health 2021, 18, 6004.
50	13.	Wilke, J.; Mohr, L.; Tenforde, A.S.; Vogel, O.; Hespanhol, L.; Vogt, L.; Verhagen, E.; Hollander, K.
51 52		Activity and health during the SARS-CoV2 pandemic (ASAP): study protocol for a multi-national
52 53	4.4	network trial. Front Med 2020 , 7, 302.
54	14.	Wilke, J.; Mohr, L.; Tenforde, A.S.; Edouard, P.; Fossati, C.; González-Gross, M.; Ramirez, C.S.; Laiño, F.; Tan, B.; Pillay, J.D. Restrictercise! Preferences regarding digital home training programs
55		Lanio, F., Fail, B., Fillay, J.D. Nestricleruse: Freierences regarding digital nonne training programs
56 57		
57 58		16
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	during confinements associated with the COVID-19 pandemic. Int J Environ Res Public Health 2020 , 17, 6515.
15.	 Wilke, J.; Mohr, L.; Tenforde, A.S.; Edouard, P.; Fossati, C.; González-Gross, M.; Sánchez Ramírez, C.; Laiño, F.; Tan, B.; Pillay, J.D. A pandemic within the pandemic? Physical activity levels substantially decreased in countries affected by COVID-19. <i>Int J Environ Res Public Health</i> 2021, <i>18</i>, 2235.
16.	Wilke, J.; Hollander, K.; Mohr, L.; Edouard, P.; Fossati, C.; González-Gross, M.; Sánchez Ramírez, C.; Laiño, F.; Tan, B.; Pillay, J.D. Drastic reductions in mental well-being observed globally during the COVID-19 pandemic: results from the ASAP survey. <i>Front Med</i> 2021 , <i>8</i> , 246.
17.	Danquah, I.H.; Petersen, C.B.; Skov, S.S.; Tolstrup, J.S. Validation of the NPAQ-short–a brief questionnaire to monitor physical activity and compliance with the WHO recommendations. <i>BMC Public Health</i> 2018 , <i>18</i> , 1-10.
18.	Bahr, R.; Clarsen, B.; Derman, W.; Dvorak, J.; Emery, C.A.; Finch, C.F.; Hägglund, M.; Junge, A.; Kemp, S. International Olympic Committee consensus statement: methods for recording and reporting of epidemiological data on injury and illness in sports 2020 (including the STROBE extension for sports injury and illness surveillance (STROBE-SIIS)). <i>Orthop J Sports Med</i> 2020 , <i>8</i> , 2325967120902908.
19.	Topp, C.W.; Østergaard, S.D.; Søndergaard, S.; Bech, P. The WHO-5 Well-Being Index: a systematic review of the literature. <i>Psychother Psychosom</i> 2015 , <i>84</i> , 167-176, doi:10.1159/000376585.
20.	Sitthipornvorakul, E.; Janwantanakul, P.; Purepong, N.; Pensri, P.; van der Beek, A.J. The association between physical activity and neck and low back pain: a systematic review. <i>Eur Spine J</i> 2011 , <i>20</i> , 677-689.
21.	Ortiz-Hernández, L.; Tamez-González, S.; Martínez-Alcántara, S.; Méndez-Ramírez, I. Computer use increases the risk of musculoskeletal disorders among newspaper office workers. <i>Arch Med Res</i> 2003 , <i>34</i> , 331-342.
22.	Janwantanakul, P.; Pensri, P.; Jiamjarasrangsi, W.; Sinsongsook, T. Associations between prevalence of self-reported musculoskeletal symptoms of the spine and biopsychosocial factors among office workers. <i>J Occup Health</i> 2009 , 0901270054-0901270054.
23.	Cagnie, B.; Danneels, L.; Van Tiggelen, D.; De Loose, V.; Cambier, D. Individual and work related risk factors for neck pain among office workers: a cross sectional study. <i>Eur Spine J</i> 2007 , <i>16</i> , 679-686.
24.	Briggs, A.M.; Smith, A.J.; Straker, L.M.; Bragge, P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. <i>BMC Musculoskelet Disord</i> 2009 , <i>10</i> , 1-12.
25.	Heneghan, N.R.; Baker, G.; Thomas, K.; Falla, D.; Rushton, A. What is the effect of prolonged sitting and physical activity on thoracic spine mobility? An observational study of young adults in a UK university setting. <i>BMJ Open</i> 2018 , <i>8</i> , e019371.
26.	Hendrick, P.; Milosavljevic, S.; Hale, L.; Hurley, D.; McDonough, S.; Ryan, B.; Baxter, G. The relationship between physical activity and low back pain outcomes: a systematic review of observational studies. <i>Eur Spine J</i> 2011 , <i>20</i> , 464-474.
27.	Heneweer, H.; Vanhees, L.; Picavet, H.S.J. Physical activity and low back pain: a U-shaped
28.	relation? <i>Pain</i> 2009 , <i>143</i> , 21-25. Bobinski, F.; Ferreira, T.A.A.; Córdova, M.M.; Dombrowski, P.A.; da Cunha, C.; do Espírito Santo, C.C.; Poli, A.; Pires, R.G.W.; Martins-Silva, C.; Sluka, K.A. Role of brainstem serotonin in analgesia produced by low-intensity exercise on neuropathic pain following sciatic nerve injury in mice.

BMJ Open

29.	Sluka, K.A.; O'Donnell, J.M.; Danielson, J.; Rasmussen, L.A. Regular physical activity prevents development of chronic pain and activation of central neurons. <i>J Appl Physiol</i> 2013 , <i>114</i> , 725-733.
30.	Stagg, N.J.; Mata, H.P.; Ibrahim, M.M.; Henriksen, E.J.; Porreca, F.; Vanderah, T.W.; Philip Malan, T. Regular exercise reverses sensory hypersensitivity in a rat neuropathic pain model: role of endogenous opioids. <i>Anesthesiology</i> 2011 , <i>114</i> , 940-948.
31.	Geva, N.; Defrin, R. Enhanced pain modulation among triathletes: a possible explanation for their exceptional capabilities. <i>Pain</i> 2013 , <i>154</i> , 2317-2323.
32.	Naugle, K.M.; Ohlman, T.; Naugle, K.E.; Riley, Z.A.; Keith, N.R. Physical activity behavior predicts endogenous pain modulation in older adults. <i>Pain</i> 2017 , <i>158</i> , 383-390.
33.	Naugle, K.M.; Riley, J.L. Self-reported physical activity predicts pain inhibitory and facilitatory function. <i>Med Sci Sports Exerc</i> 2014 , <i>46</i> , 622.
34.	Radak, Z.; Chung, H.Y.; Koltai, E.; Taylor, A.W.; Goto, S. Exercise, oxidative stress and hormesis. <i>Ageing Res Rev</i> 2008 , <i>7</i> , 34-42.
35.	Woods, J.A.; Wilund, K.R.; Martin, S.A.; Kistler, B.M. Exercise, inflammation and aging. <i>Aging Dis</i> 2012 , <i>3</i> , 130.
36.	Dhondt, E.; Danneels, L.; Van Oosterwijck, S.; Palmans, T.; Rijckaert, J.; Van Oosterwijck, J. The influence of physical activity on the nociceptive flexion reflex in healthy people. <i>Eur J Pain</i> 2021 , <i>25</i> , 774-789.
37.	Tour, J.; Löfgren, M.; Mannerkorpi, K.; Gerdle, B.; Larsson, A.; Palstam, A.; Bileviciute-Ljungar, I.; Bjersing, J.; Martin, I.; Ernberg, M., et al. Gene-to-gene interactions regulate endogenous pain modulation in fibromyalgia patients and healthy controls-antagonistic effects between opioid and serotonin-related genes. <i>Pain</i> 2017 , <i>158</i> , 1194-1203, doi:10.1097/j.pain.00000000000896.
8.	Tantimonaco, M.; Ceci, R.; Sabatini, S.; Catani, M.V.; Rossi, A.; Gasperi, V.; Maccarrone, M. Physical activity and the endocannabinoid system: an overview. <i>Cell Mol Life Sci</i> 2014 , <i>71</i> , 2681- 2698.
39.	Ham, S.A.; Kruger, J.; Tudor-Locke, C. Participation by US adults in sports, exercise, and recreational physical activities. <i>J Phys Act Health</i> 2009 , <i>6</i> , 6-14.
10.	Rhim, H.C.; Kim, S.J.; Jeon, J.S.; Nam, H.W.; Jang, K.M. Prevalence and risk factors of running- related injuries in Korean non-elite runners: a cross-sectional survey study. <i>J Sports Med Phys</i> <i>Fitness</i> 2021 , <i>61</i> , 413-419, doi:10.23736/s0022-4707.20.11223-4.
41.	Dunlop, D.D.; Song, J.; Lee, J.; Gilbert, A.L.; Semanik, P.A.; Ehrlich-Jones, L.; Pellegrini, C.A.; Pinto, D.; Ainsworth, B.; Chang, R.W. Physical activity minimum threshold predicting improved function in adults with Lower-Extremity symptoms. <i>Arthritis Care Res</i> 2017 , <i>69</i> , 475-483.
42.	Valanou, E.; Bamia, C.; Trichopoulou, A. Methodology of physical-activity and energy- expenditure assessment: a review. <i>J Public Health</i> 2006 , <i>14</i> , 58-65.
	Schmier, J.; Halpern, M. Patient recall and recall bias of health state and health status. Expert

Country	ARG	AUS	AUT	BRA	CHE	CHL	DEU	ESP	FRA	ITA	NLD	SGP	gusa	ZAF	Others	Total
Sex (M/F)	429/494	56/248	192/546	620/948	115/212	471/766	696/1356	310/277	1200/1046	348/453	50/129	437/434	364/711	236/293	108/122	5632/803
Age (SD)	37.1 (15.4)	41.6 (14.1)	27.3 (9.6)	34.2 (10.6)	37.3 (11.5)	31.5 (13.6)	40.4 (16.3)	43.0 (13.4)	43.3 (16.9)	38.5 (15.3)	47.5 (14.0)	40.1 (12.1)	6 43.1 6 14.0)	32.4 (14.3)	40.0 (13.5)	38.3 (15.1)
WHO-5 (SD)	54.3 (17.8)	50.1 (14.8)	55.0 (16.5)	53.0 (16.0)	50.4 (15.2)	54.7 (18.2)	52.9 (17.0)	49.2 (15.8)	48.3 (14.8)	56.3 (17.3)	49.0 (14.7)	52.2 (17.6)	ten 49.4 ten 14.9)	52.2 (21.1)	51.2 (17.2)	52.0 (16.8)
Employment (Yes, %)	61.9	86.8	62.7	78.8	96.0	59.2	73.2	79.8	69.9	65.9%	77.1	88.8	r 2084.1	53.7	85.0	72.8
MVPA (SD)	488.7 (596.2)	352.3 (340.0)	384.6 (408.7)	396.4 (454.9)	379.0 (458.1)	385.7 (518.3)	438.6 (481.3)	493.2 (617.0)	527.9 (516.0)	566.2 (635.3)	506.5 (420.5)	376.5 (445.7)	48.0)	310.6 (455.8)	437.8 (529.7)	439.5 (498.7)
VPA (SD)	218.7 (338.0)	121.3 (152.4)	141.4 (206.5)	202.0 (305.7)	130.6 (152.6)	153.9 (287.9)	146.9 (226.5)	188.4 (295.2)	234.7 (343.3)	247.2 (350.1)	200.2 (225.7)	171.0 (302.4)	ର୍ଯ୍ 95.9 (ଅ30.0)	144.1 (272.7)	203 (275.6)	186.4 (288.8)

Abbreviations: F, Female; M, Male; MVPA, Moderate to Vigorous Physical Activity; SD, Standard Deviation; VPA, Vigorous Physical Activity, WHO-5, The 5item World Health Organization Well-Being Index

Jev. , Switzerland; CH. south Africa Country Abbreviations: ARG, Argentina; AUS, Australia; AUT, Austria; BRA, Brazil; CHE, Switzerland; CHL, Chile; DEU, Germany; ESP, Spain; FRA, France; ITA, Italy; NLD, Netherlands; SGP, Singapore; USA, United States of America; ZAF, South Africa

bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright.

36/bmjopen-2

BMJ Open

Table 2. Association of PA with MSK-Pain by Anatomical Locations

			<u> </u>									
Location of	150-3	00 min	300-450 min 4			ose of WHO Guideline-Based PA -600 min 600-750 min		750900 min		900+ min		
MSK-Pain	Crude OR	Adjusted OR	Crude OR	Adjusted OR	Crude OR	Adjusted OR	Crude OR	Adjusted OR	Crude OR _N		Crude OR	Adjusted O
	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)
	0.89	0.99	0.76	0.89	0.66	0.78	0.62	0.75	0.63		0.59	0.78
Neck/Cervical	(0.79-1.01)	(0.87-1.12)	(0.67-0.88)	(0.77-1.03)	(0.57-0.76)	(0.67-0.91)	(0.52-0.74)	(0.62-0.90)	(0.52-0.77)		(0.52-0.67)	(0.68-0.89
<u>(1)</u>	0.87	0.92	0.87	0.94	0.83	0.93	0.80	0.88	1.10 (0.90-1.34)	1.27	0.98	1.16
Shoulder	(0.75-1.00)	(0.79-1.06)	(0.74-1.02)	(0.79-1.10)	(0.71-0.99)	(0.79-1.11)	(0.66-0.98)	(0.72-1.08)	(0.90-1.34	(1.04-1.56)	(0.85-1.13)	(1.00-1.34
TT	0.77	0.98	0.60	0.81	0.56	0.76	0.62	0.81	0.89 E	1 23	0.73	1.01
Upper arm	(0.60-1.00)	(0.76 - 1.27)	(0.44-0.81)	(0.60-1.11)	(0.41-0.77)	(0.54 - 1.05)	(0.42-0.89)	(0.55-1.19)	(0.63-1.28)	(0.85-1.80)	(0.56-0.94)	(0.77-1.33
Elhory	0.73	0.77	0.64	0.70	0.95	0.99	0.92	0.93			1.19	1.30
Elbow	(0.54-0.97)	(0.57 - 1.03)	(0.46-0.89)	(0.50-0.98)	(0.70-1.30)	(0.72 - 1.37)	(0.64-1.32)	(0.64-1.37)	0.90 0.60-1.34	(0.62-1.42)	(0.93-1.53)	(0.99-1.70
Forearm	0.91	1.08	0.53	0.63	0.72	0.85	0.80	0.96	0.74	0.90	0.98	1.17
Forearm	(0.65-1.28)	(0.76-1.52)	(0.34-0.82)	(0.40-0.99)	(0.47-1.07)	(0.55-1.30)	(0.50-1.29)	(0.59-1.55)	(0.43-1.26)	(0.52-1.54)	(0.70-1.36)	(0.82-1.6
Wrist	0.86	1.07	0.57	0.74	0.63	0.81	0.79	1.00	0.71 <u>n</u>	0.95	0.86	1.15
WIISt	(0.70-1.07)	(0.86-1.34)	(0.43-0.74)	(0.57-0.98)	(0.48-0.82)	(0.62-1.07)	(0.58-1.06)	(0.74-1.37)	(0.50-0.99		(0.70-1.07)	(0.91-1.4
Hand	0.68	0.81	0.44	0.57	0.47	0.59	0.60	0.74	0.60 00 00 00 00 00 00 00 00 00 00 00 00 0	0.77	0.57	0.74
Tiuliu	(0.53-0.88)	(0.62-1.05)	(0.32-0.61)	(0.40-0.79)	(0.34-0.66)	(0.41-0.83)	(0.41-0.87)	(0.50-1.09)	(0.40-0.91)	(0.50-1.18)	(0.44-0.75)	(0.56-0.9
Fingers	0.85	0.91	0.63	0.72	0.65	0.71	0.80	0.93	0.71 O		0.75	0.84
1	(0.66-1.10)	(0.70-1.19)	(0.46-0.86)	(0.52-0.99)	(0.47-0.86)	(0.51-0.99)	(0.56-1.14)	(0.65-1.34)	(0.48-1.07)	· · · · · · · · · · · · · · · · · · ·	(0.58-0.98)	(0.64-1.1
Thoracic spine	0.75	0.77	0.83	0.90	0.71	0.78	0.69	0.74		0.64	0.63	0.77
1	(0.63-0.90) 0.85	(0.64-0.93) 0.98	(0.69-1.02) 0.74	(0.74-1.10) 0.88	(0.58-0.88)	(0.63-0.97) 0.74	(0.54-0.89) 1.04	(0.57-0.97)	(0.40-0.73)		(0.52-0.76) 0.78	(0.63-0.9) 0.90
Ribs	(0.85) (0.59-1.21)	(0.68-1.42)	(0.49-1.11)	(0.58-1.34)	0.60 (0.38-0.95)	0.74 (0.46-1.17)	(0.66-1.62)	1.18 (0.73-1.88)	0.69		(0.54-1.11)	(0.62-1.3
	0.91	0.93	0.85	0.91	0.77	0.84	0.69	0.76	0.85	0.96	0.79	0.93
Lower back	(0.80-1.03)	(0.82-1.06)	(0.73-0.97)	(0.78-1.05)	(0.67-0.90)	(0.72-0.97)	(0.57-0.82)	(0.63-0.91)	(0.71-1.03)		(0.70-0.90)	(0.81-1.0
	0.70	0.94	0.45	0.61	0.68	0.97	0.67	0.89	0.91		0.60	0.82
Abdomen	(0.52-0.95)	(0.69-1.28)	(0.31-0.67)	(0.41-0.91)	(0.48-0.97)	(0.68-1.40)	(0.44-1.02)	(0.57-1.37)	(0.60-1.38)		(0.44-0.83)	(0.59-1.1
	1.00	1.11	0.77	0.86	0.92	1.13	1.02	1.15	0 96 <	1 1 9	1.10	1.37
Pelvis/Gluteals	(0.78-1.28)	(0.86-1.43)	(0.57-1.03)	(0.64-1.17)	(0.69-1.23)	(0.84-1.52)	(0.74-1.41)	(0.81-1.62)	(0.67-1.39)	(0.82-1.73)	(0.86-1.40)	(1.06-1.7
TT'	1.06	1.05	0.93	0.96	1.05	1.09	0.93	0.97	1.24 ⋛	1.37	0.97	1.17
Hip	(0.87-1.30)	(0.85-1.29)	(0.74-1.17)	(0.76 - 1.21)	(0.84-1.32)	(0.87-1.38)	(0.71-1.22)	(0.73-1.29)	1.24 ₽ (0.94-1.63)	(1.03-1.81)	(0.79-1.18)	(0.95-1.4
с ·	0.94	1.04	0.72	0.80	0.98	1.05	1.08	1.20	1.31 式	1.40	1.28	1.40
Groin	(0.65-1.34)	(0.72 - 1.49)	(0.47-1.10)	(0.52-1.23)	(0.65-1.46)	(0.69-1.59)	(0.69-1.71)	(0.75-1.91)	(0.83-2.10) <u></u>	(0.87-2.27)	(0.92-1.79)	(0.99-1.9
Thigh	0.99	1.13	0.87	0.99	1.24	1.41	1.39	1.59	1.60 N	1.82	1.37	1.51
Ingn	(0.75-1.31)	(0.85-1.51)	(0.63-1.19)	(0.71-1.38)	(0.92-1.68)	(1.03-1.92)	(0.99-1.95)	(1.13-2.25)	1.60 (1.13-2.27) 1.43	(1.28-2.61)	(1.05-1.78)	(1.15-1.9
Knee	1.02	1.08	1.04	1.10	1.17	1.25	1.12	1.22	1.43 0	1.55	1.16	1.30
KIEC	(0.88-1.19)	(0.92-1.25)	(0.88-1.22)	(0.93-1.30)	(0.99-1.37)	(1.06-1.50)	(0.93-1.36)	(1.01-1.49)	(1.18-1.75) 0.95	(1.27-1.90)	(1.00-1.34)	(1.12-1.5
Lower leg	0.77	0.93	0.82	1.04	1.02	1.31	1.14	1.43			1.03	1.34
Lowerneg	(0.59-1.00)	(0.71-1.21)	(0.62-1.07)	(0.78-1.39)	(0.77-1.34)	(0.98-1.73)	(0.83-1.55)	(1.04-1.97)	(0.66-1.36)	(0.85-1.77)	(0.81-1.31)	(1.04-1.7
Ankle/Achilles	1.09	1.14	1.19	1.24	1.42	1.47	1.48	1.55	1.70 e	1.79	1.69	1.85
	(0.87-1.36)	(0.90-1.43)	(0.93-1.52)	(0.96-1.59)	(1.12-1.81)	(1.14-1.88)	(1.12-1.94)	(1.17-2.06)	(1.28-2.26 P	(1.34-2.40)	(1.37-2.08)	(1.49-2.3
Foot/Toes	1.22	1.28	1.12	1.25	1.08	1.24	1.10	1.26	1.23		1.17	1.53
root/loes	(0.99-1.52)	(1.02 - 1.60)	(0.88-1.42)	(0.98 - 1.61)	(0.84-1.38)	(0.96 - 1.60)	(0.82-1.47)	(0.93 - 1.71)	(0.91-1.67	(1.10-2.05)	(0.94-1.45)	(1.22-1.9

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Abbreviations: CI, Confidence Interval; MSK, Musculoskeletal; OR, Odds Ratio; PA, Physical Activity; WHO, World Health Brganization Footnote: A group of participants who did not meet the WHO recommendations of PA (i.e. PA less than 150 min per week) was set as the reference group. The model was adjusted for sex, age, employment status, and depression risk. The numbers in bold denote significant results, and the confidence interval that starts or ends with 1.0 derives from rounding the decimals.

Table 3. Association of PA with the Number of MSK-Pain Locations

Number of MSK-Pain Locations		Dose of WHO Guideline-Based PA										
	150-300 min		300-450 min		450-600 min		600-750 min		750 -9 00 min		900+ min	
	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	5	Crude OR (95% CI)	Adjusted OR (95% CI)
Minimum	1.06	1.10	1.04	1.12	1.01	1.11	0.92	1.04	1.09	1.28	1.05	1.30
1 location	(0.95-1.18)	(0.98-1.23)	(0.93-1.17)	(0.99-1.27)	(0.89-1.14)	(0.98-1.26)	(0.80-1.06)	(0.90-1.20)	(0.80-1.28)	(1.10-1.51)	(0.94-1.17)	(1.16-1.45)
Minimum	0.89	0.97	0.80	0.90	0.80	0.93	0.86	1.00	0.93		0.88	1.08
3 locations	(0.78-1.01)	(0.85-1.11)	(0.70-0.93)	(0.78-1.04)	(0.69-0.93)	(0.80-1.08)	(0.72-1.02)	(0.84-1.19)	(0.77-1.12)		(0.77-0.99)	(0.94-1.23)
Minimum	0.76	0.84	0.65	0.75	0.61	0.73	0.74	0.85	0.87	1.09	0.83	1.06
5 locations	(0.62-0.93)	(0.69-1.03)	(0.51-0.82)	(0.60-0.95)	(0.48-0.78)	(0.57-0.93)	(0.56-0.97)	(0.64-1.13)	(0.66-1.16)	(0.82-1.45)	(0.68-1.01)	(0.87-1.29)
Minimum	0.70	0.76	0.32	0.36	0.57	0.64	0.64	0.67	0.62	0.70	0.61	0.67
10 locations	(0.45-1.07)	(0.49-1.17)	(0.17-0.61)	(0.19-0.68)	(0.34-0.98)	(0.37-1.10)	(0.35-1.19)	(0.35-1.40)	(0.31-1.23)	(0.35-1.40)	(0.39-0.95)	(0.42-1.06)


Abbreviations: CI, Confidence Interval; MSK, Musculoskeletal; OR, Odds Ratio; PA, Physical Activity; WHO, World Health Organization Footnote: A group of participants who did not meet the WHO recommendations of PA (i.e. PA less than 150 min per week) was set as the reference group. The model was adjusted for sex, age, employment status, and depression risk.

njopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright.

36/bmjop

g

https://survey.studiumdigitale.uni-frankfurt.de/admin/preview.php?t=4o7... BMJ Open



	Page
Please indicate your sex.	SD01 🗉
O Male	
○ Female	
O Non-binary	
◯ I prefer not to say	
What is your age?	SD02 -
years	
	SD04 -
Where do you live?	
[Please choose] v	
	SD03
Where do you work since the virus outbreak in your country?	
Remotely (Home office)	
Office/regular place of work	
O both	
○ I do not have a formal employment.	
◯ I do not want to tell.	
	Page
	A
Do you currently work part-time or full-time?	SD05 🗉
◯ full-time	
O part-time	
 I do not want to tell 	
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

	Page 04 KI
Have you had any symptoms beyond a minor respiratory tract infection since the viru country?	-
Only choose yes, if you had to stay in bed or reduce your regular movement behavio	ur due to these symptoms.
O yes	
O no	
	Page 0
	Coror
	КН02 🗉
Have you been diagnosed with the novel Coronavirus?	
Only choose "yes" if you have been diagnosed by a helathcare professional.	
⊖ yes	
O no	
○ I do not want to tell	
	Page 0
	Einschraenku
Please indicate the approximate number of days you have been limited in your ability move freely due to restrictions of public life (e.g. prohibition of face-to-face contact, l lockdowns).	
days	
days	
days	
days	Page 0
days	-
days	Erklaeru
From here, we will repeatedly ask how certain situations and conditions have changed in yo of the novel coronavirus. For instance, if you just stated to be restricted in your ability to mo please always compare the situation during these last 14 days to 14 typical days prior to the	Erklaeru bur country since the outprea ve freely since 14 days,
From here, we will repeatedly ask how certain situations and conditions have changed in you of the novel coronavirus. For instance, if you just stated to be restricted in your ability to mo please always compare the situation during these last 14 days to 14 typical days prior to the days, please compare these 30 days with 30 typical days prior to the outbreak.	Erklaeru bur country since the outprea ve freely since 14 days,
From here, we will repeatedly ask how certain situations and conditions have changed in yo of the novel coronavirus. For instance, if you just stated to be restricted in your ability to mo please always compare the situation during these last 14 days to 14 typical days prior to the	Erklaeru bur country since the outprea ve freely since 14 days,
From here, we will repeatedly ask how certain situations and conditions have changed in yo of the novel coronavirus. For instance, if you just stated to be restricted in your ability to mo please always compare the situation during these last 14 days to 14 typical days prior to the	Erklaeru bur country since the outprea ve freely since 14 days,
From here, we will repeatedly ask how certain situations and conditions have changed in yo of the novel coronavirus. For instance, if you just stated to be restricted in your ability to mo please always compare the situation during these last 14 days to 14 typical days prior to the	Erklaeru bur country since the outprea ve freely since 14 days,
From here, we will repeatedly ask how certain situations and conditions have changed in yo of the novel coronavirus. For instance, if you just stated to be restricted in your ability to mo please always compare the situation during these last 14 days to 14 typical days prior to the	Erklaeru our country since the outorea ve freely since 14 days, e outbreak. If you chose 30

		Page 08 KAFrei
		NAFIE
hysical activities in I	eisure time	KA09
would like to know,	, how physically active you have been in your free time (including commuting fror lerate and vigorous activities – light activities do not need to be reported.	n and to work).
	e those where your hearbeat increases and you breathe faster (e.g. brisk walkin is a exercise, heavy gardening, running or recreational sports).	g, cycling as a
	those that get your heart racing, make you sweat and so short of breath that you f running, cycling at high speeds, cardio training, weigh-lifting or team sports such as	
oderate and vigorou	is activities	KA01 🗉
-	much time do you spend in total on both moderate and vigorous physical activities?	>
	s with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity	
before the outbreak	Minutes per week.	
since the outbreak	Minutes per week.	
10 minutes.	s with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity	
before the outbreak	Minutes per week.	
since the outbreak	Minutes per week.	

hysical activity in your job 						Page к
While the previous questions addressed free time, the following two focus on work/occupational time. Again, we on bout moderate and vigorous activities – light activities do not need to be reported. Acderate activities are those where your hearbeat increases and you breathe faster (e.g. brisk walking). figorous activities are those that get your heart racing, make you sweat and so short of breath that you find it diffigorous activities are those that get your heart racing, make you sweat and so short of breath that you find it diffigorous activities are those where your heart racing, make you sweat and so short of breath that you find it diffigorous activities are those where your heart racing, make you sweat and so short of breath that you find it diffigorous activities are those where your heart racing, make you sweat and so short of breath that you find it diffigorous activities are those where your heart racing, make you sweat and so short of breath that you find it diffigorous activities are those where your heart racing, make you sweat and so short of breath that you find it diffigorous activities are those where your heart racing, make you sweat and so short of breath that you find it diffigorous activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more 0 minutes. Infigorous activities only KAO Values sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more 0 minutes. Infigorous activities only Mainutes per week. Since the outbreak Minutes per week. Since the outbreak Minutes per week. Since the outbreak Minutes per week.						KA10
Iggrous activities are those that get your heart racing, make you sweat and so short of breath that you find it diffipeak (e.g. repeated lifting of heavy weights). Moderate and vigorous activities On a typical week, how much time do you spend in total on both moderate and vigorous physical activities? Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of m 0 minutes. before the outbreak Minutes per week. since the outbreak Minutes per week. Vigorous activities only KAO own much of that time you indicated above, do you spend in total on vigorous physical activities only? Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more 0 minutes. before the outbreak Minutes per week. since the outbreak Minutes per week. single and very light activities						time. Again, we only
peak (e.g. repeated lifting of heavy weights). Image: Comparison of the every weights). Adderate and vigorous activities Defense and vigorous activities Defense sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of n 0 minutes. Image: Comparison of the every service week. before the outbreak Minutes per week. since the outbreak Minutes per week. rigorous activities only Image: Comparison of the every service week. rigorous activities only Image: Comparison of the every service week. rigorous activities only Image: Comparison of the every service week. rigorous activities only Image: Comparison of the every service week. rigorous activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more 0 minutes. before the outbreak Minutes per week. since the outbreak Minutes	Moderate activities are	those where	your hearbeat	t increases and you br	eathe faster (e.g. brisk wa	alking).
Addrate and vigorous activities Rah On a typical week, how much time do you spend in total on both moderate and vigorous physical activities? Rah Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of m Image: Comparison of the minimal duration of 10 minutes. Enter 0, if there was not at least one activity of m before the outbreak Minutes per week. since the outbreak Minutes per week. rigorous activities only Kao Yelease sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more 0 minutes. Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more 0 minutes. before the outbreak Minutes per week. since the outbreak Minutes per week. Page Activities Minutes per week. Page Activities Page Activities Please indicate the impact of the restrictions in public life on your overall level of activity (now including are sight and very light activities such as shopping, walking, etc.) strongly negative slight negative modest positive strong				acing, make you swea	at and so short of breath	that you find it difficu
Phon a typical week, how much time do you spend in total on both moderate and vigorous physical activities? Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of n 0 minutes. before the outbreak Minutes per week. since the outbreak Minutes per week. figorous activities only for minutes. figorous activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more 0 minutes. figorous activities only figorous activities only figorous activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more 0 minutes. figorous activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more 0 minutes. before the outbreak Minutes per week. since the outbreak Minutes per week. since the outbreak Minutes per week. Figorous activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more 0 minutes. Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more 0 minutes. Please indicate the impact of the restrictions in public life on your overall level of activity (now including are fight and very light activities such as shopping, walking, etc.) strongly negative slight negative modest positive strongly positi influence influence no influence impact influence	Moderate and vigorou	is activitios				KA07
Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of r 0 minutes. before the outbreak Minutes per week. since the outbreak Minutes per week. figorous activities only tow much of that time you indicated above, do you spend in total on vigorous physical activities only? Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more 0 minutes. before the outbreak Minutes per week. since the outbreak Minutes per week. Strongly negative slight negative no influence modest positive strongly positi influence influence no influence modest positive strongly positi	-		o vou spend i	n total on both modera	ate and vigorous physical	Rahm
since the outbreak Minutes per week. Migorous activities only Minutes per week. Minutes you indicated above, do you spend in total on vigorous physical activities only? Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more 0 minutes. before the outbreak Minutes per week. since the outbreak Minutes per week. Please indicate the impact of the restrictions in public life on your overall level of activity (now including ansight and very light activities such as shopping, walking, etc.) strongly negative slight negative no influence modest positive strongly positi influence					0 1 1	
Arigorous activities only (KAQ) How much of that time you indicated above, do you spend in total on vigorous physical activities only? Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more 0 minutes. Defore the outbreak Minutes per week. since the outbreak Minutes per week. Please indicate the impact of the restrictions in public life on your overall level of activity (now including at sight and very light activities such as shopping, walking, etc.) strongly negative slight negative strongly negative slight negative influence no influence modest positive strongly positiinfluence	before the outbreak] Minutes per	week.		
//gorous activities only How much of that time you indicated above, do you spend in total on vigorous physical activities only? Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more 0 minutes. Defore the outbreak Minutes per week. Since the outbreak Minutes per week. Since the outbreak Minutes per week. Page Aktivitaets Please indicate the impact of the restrictions in public life on your overall level of activity (now including ansight and very light activities such as shopping, walking, etc.) strongly negative slight negative influence no influence impact	since the outbreak] Minutes per	week.		
Page Aktivitaets Please indicate the impact of the restrictions in public life on your overall level of activity (now including ans ight and very light activities such as shopping, walking, etc.) strongly negative slight negative strongly positi influence influence impact influence						
Aktivitaets Please indicate the impact of the restrictions in public life on your overall level of activity (now including and right and very light activities such as shopping, walking, etc.) strongly negative slight negative strongly positi influence influence no influence impact influence	SINCE THE OUTDREAK		vinutes per w			
Please indicate the impact of the restrictions in public life on your overall level of activity (now including and ight and very light activities such as shopping, walking, etc.) strongly negative slight negative modest positive strongly positi influence influence no influence impact influence				/eek.		
Please indicate the impact of the restrictions in public life on your overall level of activity (now including and ight and very light activities such as shopping, walking, etc.) strongly negative slight negative modest positive strongly positi influence influence no influence impact influence				/eek.		Page
influence influence no influence impact influence				/eek.		Page Aktivitaetsni
0 0 0 0				n public life on your o	overall level of activity (Aktivitaetsni
	light and very light ac strongly negative	slight no	as shopping	n public life on your o I, walking, etc.)	modest positive	Aktivitaetsni
	light and very light ac strongly negative	slight no	as shopping	n public life on your o , walking, etc.) no influence	modest positive	Aktivitaetsni now including also strongly positive influence

	Раде 11 каз
How did you engage in sport or exercise before the virus outbreak in your country?	KA05 🗉
Multiple choice possible.	
Gym	
Sports club	
Self-organised outdoor (e.g. running, cycling in nature)	
Self-organised at home (e.g. cycle ergometer, dumbbells)	
□ others	
not at all	
How did you engage in sport or exercise since the virus outbreak in your country?	KA06 🗉
Multiple choice possible.	
self-organised outdoor (e.g. running, cycling in nature)	
self-organised at home (e.g. cycle ergometer, dumbbells)	
others	
not at all	
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open: first published as 10.1136/bmjopen-2021-059525 on 19 September 2022. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright.

						Page 12 Pain
Please indicate whether you suffered f	from musculoskeletal pain	<u>before</u> ar	nd/or <u>sinc</u>	<u>e</u> the virus	outbreal	к. (WB13 🗉
The musculoskeletal system comprises a and their functions.	ll parts of the skeletal syster	n with bon	es, muscle	es, ligament	s, tendor	ns, joints
	no pain	very light pain	light pain	moderate pain	strong pain	very strong pain
pefore outbreak	0	0	0	0	0	0
ince outbreak	0	0	0	0	0	0
low much did pain interfere with your	normal work (including be	oth work o	outside th	e home and	l housev	WB14 • WOTK) ?
	no pain	not at all	a little bit	moderately	quite a bit	extremely
before outbreak	0	0	0	0	0	0
since outbreak	0	0	0	0	0	0
For peer review o	nly - http://bmjopen.bmj.con	n/site/abou	ıt/guidelin	es.xhtml		

		Page 1 Checklis
question('WB15', 'combine=WB16')		(WB15 🗉
Please list all body regions where you had pain <u>before</u> (left boxes) and	i/or <u>side</u> (right boxes) the onse	et WB16 🗉
Multiple selections in both columns are possible.	before outbreak	since outbreak
I did not have pain.		
Neck/cervical spine		
Shoulder		
Upper arm		
Elbow		
Forearm		
Wrist		
Hand		
Fingers		
Thoracic spine/upper back		
Sternum/Ribs		
Lumbar spine/lower back		
Abdomen		
Pelvis/buttock		
Нір		
Groin		
Thigh		
Knee		
Lower leg		
Ankle/achilles tendon		
Foot/toes		
For peer review only - http://bmjopen.bmj.com/site/ab	oout/guidelines.xhtml	

WHO5

Please indicate for each of the five statements which is closest to how you have been feeling before the	WB10 OULDIEAK
of the novel coronavirus.	

	all the time	most of the time	a little more than half of the time	a little less than half of the time	every now and then	at no time
Before the outbreak						
I have felt cheerful and in good spirits	0	0	0	0	0	0
I have felt calm and relaxed	0	0	0	0	0	0
I have felt active and vigorous	0	0	0	0	0	0
I woke up feeling fresh and rested	0	0	0	0	0	0
my daily life has been filled with things that interest me	0	0	0	0	0	0

Please indicate for each of the five statements which is closest to how you have been feeling since the outpreak of the novel coronavirus.

	all the time	most of the time	a little more than half of the time	a little less than half of the time	every now and then	at no time
Since the outbreak						
I have felt cheerful in good spirits	0	0	0	0	0	0
I have felt calm and relaxed	0	0	0	0	0	0
I have felt active and vigorous	0	0	0	0	0	0
I woke up feeling fresh and rested	0	0	0	0	0	0
my daily life has been filled with things that interest me	0	0	0	0	0	0

										Page
In general, ł closure of s	how woul	d you rate ilities and	e the influence I gyms, bans	ce of res s of publ	strictions by g	governm or quarar	ent due to ti ntine) on yo	he novel c ur person	oronavir al well-be	WB19 rus (e.g., eing?
psychologic	cal well-b	eing								
strong negative influence					no influence					stror positi influer
		0	0	0	0	0	0	0	0	WB20
strong negative influence		0	0	0	no influence	0	0	0	0	stror positi influer
0	0	0	0	0	0	0	0	0	0	0
Since the ou situation.	utbreak o	f the nove	el coronaviru	ıs, sport	and/or phys	ical activ	ity helps me	e deal with	n the ove	(WB12 rali
Situation.										
completely disagree			rather disagree				rather agree			total agre
0	0	0	0	0	0	0	0	0	0	0
										Page
										Page
	be interes in public	sted in a f	ree online ex	kercise t	raining progr	ram that y	you could u	se home-l	oased de	_
O yes	be interes in public	sted in a f	ree online ex	kercise t	raining progr	ram that y	you could u	se home-l	based de	_
	be interes in public	sted in a fi life?	ree online ex	(ercise t	raining progr	ram that y	you could u	se home-l	based de	_
O yes	be interes in public	sted in a fi life?	ree online ex	(ercise t	raining progr	ram that y	you could u	se home-l	based de	_
O yes	be interes in public	sted in a fi	ree online ex	(ercise t	raining progr	ram that y	you could u	se home-l	oased de	
O yes	be interes in public	sted in a fi	ree online ex	kercise t	raining progr	ram that y	you could u	se home-l	based de	
O yes	be interes in public	sted in a f	ree online ex	(ercise t	raining progr	ram that y	you could u	se home-l	based de	
O yes	be interes in public	sted in a f	ree online ex	(ercise t	raining progr	ram that y	you could u	se home-l	based de	
O yes	be interes in public	sted in a fi	ree online ex	(ercise t	raining progr	ram that y	you could u	se home-l	oased de	
O yes	be interes in public	sted in a fi life?	ree online ex	(ercise t	raining progr	ram that y	you could u	se home-l	based de	
O yes	be interes in public	sted in a fi	ree online ex	(ercise t	raining progr	ram that y	you could u	se home-l	based de	
O yes	be interes in public	sted in a fi	ree online ex	kercise t	raining progr	ram that y	you could u	se home-l	based de	Page

	Page 17
	TP
How much time per week would you like to spend for such a training program?	TP02 •
Minutes per training session/workout	
How often would you like to exercise?	(TP04 🗉
O daily	
O 4-6 times a week	
O 3-4 times a week	
O 1-2 times a week	
Which type of exercise would you like to perform?	TP03
Multiple choice possible.	
Strength	
Endurance	
Coordination/Balance	
Cognition	
Flexibility/Stretching	
Relaxation	
no preference	
	Page 1
	Cod
Thank you for participating!	EN04
You are welcome to visit us on our homepage as well as on Facebook and Instagram:	EN05

You are welcome to visit us on our homepage as well as on Facebook and Instagram:



Homepage Facebook Instagram

Please feel free to share this survey with your family, work colleagues and friends! Thank you!

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Last Page

Thank you for participating!

Your answers have been saved, you can now close the browser window.

Imprint ASAP – 2020



Page 35 of 35

 BMJ Open

Section/Topic	ltem #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract θ	1-3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was	1-3
Introduction		Fundain the activities beckground and actionals for the investigation being reported	
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	3-4
Methods		load	
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, folow-up, and data collection	4-5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Gize diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-6
Bias	9	Describe any efforts to address potential sources of bias	5-6
Study size	10	Explain how the study size was arrived at	5-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which $\operatorname{gro}_{4}^{N}$ ings were chosen and why	5-6
Statistical methods	12	(<i>a</i>) Describe all statistical methods, including those used to control for confounding	5-6
		(b) Describe any methods used to examine subgroups and interactions	5-6
		(c) Explain how missing data were addressed ক্র	5-6
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
Results		copyright	

 mjopen-2021

by copyright.

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examin d for eligibility,	6
		confirmed eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on കxposures and potential confounders	6
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	7
Main results	16	(<i>a</i>) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-8
		(b) Report category boundaries when continuous variables were categorized	7-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses $\stackrel{\sf O}{\exists}$	N/A
Discussion		http://www.alianalianalianalianalianalianalianalia	
Key results	18	Summarise key results with reference to study objectives	8-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-12
Other information		April	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for 韩e original study on which the present article is based	13

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cgphort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicinegrg/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml